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SURVEILLANCE, PREVENTION AND SURGICAL TREATMENTS FOR 
HEPATOCELLULAR CARCINOMA 
Kerui Xu, Ph.D. 
University of Nebraska, 2018 
 
Supervisor: Shinobu Watanabe-Galloway, Ph.D. 
Liver cancer is the second-leading cause of cancer death, representing roughly 
9.1% of all cancer mortality. Of all primary cancers of the liver, hepatocellular carcinoma 
(HCC) accounts for roughly 85%. HCC has been increasing in the U.S. and other countries. 
In particular, HCC places a huge burden on the Chinese population, as China alone 
consists of approximately 50% of the total HCC cases and deaths. In China, chronic 
hepatitis B virus (HBV) infection is the leading cause for developing HCC. The two 
challenges in prevention and control of HCC experienced in China are low rates of HCC 
screening among the high-risk populations and poor adherence to HBV antiviral therapy. 
As of this date, there is a dearth of research in surveying high-risk populations with chronic 
viral hepatitis to evaluate the compliance, knowledge level, and self-identified barriers to 
recommended HCC screening and antiviral medication treatment. In addition to its high 
incidence and mortality rates in China, HCC is also a major disease burden in the U.S., 
where HCC is currently the fastest growing cause of cancer-related death. As HCC often 
leads to poor survival, it is critical to initiate early treatment. Currently, there are no 
established guidelines to define the optimal time interval from diagnosis to surgery. 
Knowledge regarding to the impact of HCC treatment delays is solely based on results 
produced from medical records-based studies conducted in single centers, and findings 
have been inconsistent. The main objectives of this dissertation are to 1) investigate the 
practice, knowledge and barriers for HCC screening in high-risk Chinese patients, 2) 
assess the medication adherence and perceived barriers to oral antiviral therapy for 
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chronic HBV treatment, and 3) utilize the Commission on Cancer’s National Cancer 
Database to examine the association between surgical treatment delays and long-term 
survival in HCC patients.  
In the results of the first objective, we observed that among 352 high-risk patients 
for HCC, 50.0% had routine HCC screening, 23.3% had irregular screening and 26.7% 
had incomplete or no screening. The most frequent barriers reported for not receiving 
screening were not aware that screening for HCC exists (41.5%), no symptoms or 
discomfort (38.3%), and lack of recommendation from physicians (31.9%). The results of 
the second objective showed that among 369 patients with chronic HBV, only 16.5% were 
measured with high adherence while 51.2% had low adherence utilizing the Morisky 
Medication Adherence Scale. The most common reasons for skipping HBV antiviral 
medications were that medication(s) are expensive (48.7%), forgetfulness (45.1%), have 
experienced or worry about potential side effects (19.8%). The results of the third objective 
showed that using a wait time cutoff at 60 days from the date of HCC diagnosis to definitive 
surgery, delayed patients demonstrated significantly better 5-year survival for local tumor 
destruction (29.1% vs. 27.6%) and hepatic resection (44.1% vs. 41.0%). Risk-adjusted 
model indicated that delayed patients had a 7% decreased risk of death. 
The findings of these studies may assist healthcare providers and researchers to 
develop more effective educational programs to improve patients’ awareness, knowledge 
and perceptions about HCC prevention and control, actively identify the high-risk patients 
for undergoing HCC screening, and provide better disease management and timely 
treatment for patients with chronic viral hepatitis to decrease the likelihood of developing 
HCC. For treating HCC patients, using a national hospital-based cancer registry, our study 
added new evidence that delay in HCC surgery was associated with a decreased risk of 
mortality. The finding calls for the need to conduct prospective studies to assess the case 
prioritization approach and its level of impact in HCC surgical care. 
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CHAPTER 1 
INTRODUCTION 
 
Specific aims 
According to the Global Burden of Disease 2015 study, there were an estimated 
854,000 new cases and 810,000 deaths due to liver cancer in 2015 [1]. Liver cancer is the 
sixth most common malignancy worldwide, but it is the second-leading cause of cancer 
death, representing roughly 9.1% of all cancer mortality [2]. Globally, liver cancer is the 
fifth most common cancer in males and seventh in females [2], and hepatocellular 
carcinoma (HCC) accounts for roughly 85% of primary cancer of the liver [3].  
Of all countries worldwide, HCC places a huge burden on the Chinese population, 
as China alone has about 50% of the total HCC cases and deaths [4]. In China, chronic 
hepatitis B virus (HBV) infection is the leading cause for developing HCC, and one-third 
of the world’s total populations who are chronically infected with HBV are residing in China 
[5]. The two challenges in prevention and control of HCC experienced in China are low 
rates of HCC screening among the high-risk populations and poor adherence to HBV 
antiviral therapy, which have been likely attributed by a lack of health awareness, 
inadequate knowledge about liver disease progression, and high costs associated with 
managing hepatitis infection [6-10]. As of date, there is a dearth of research in surveying 
high-risk populations with chronic viral hepatitis to evaluate the compliance, knowledge 
level, and self-identified barriers to compliance with guidelines recommended HCC 
screening and antiviral medication treatment.  
In addition to its high incidence and mortality rates in China, HCC has also become 
a major disease burden in the U.S [11], where HCC currently is the fastest growing cause 
of cancer-related death in the U.S. [11]. As HCC often leads to poor survival with an 
estimated 5-year survival rate of just 17.7% [12], it is critical to initiate early treatment once 
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diagnosis has been confirmed. Currently, there are no established guidelines to define 
surgical delay in HCC-directed surgery or the optimal time interval from diagnosis to 
surgery. Knowledge regarding the impact of HCC treatment delays is solely based on 
results produced from medical records-based studies conducted in single centers, and 
findings have been largely inconsistent [13-19].  
In this dissertation, the long-term goals are to develop more effective strategies to 
prevent or slow down disease progression to liver cancer among high-risk populations 
who are infected with chronic viral hepatitis, and to provide evidence-based 
recommendations for improved disease management and timely treatment in patients with 
liver cancer. To achieve these goals, we seek to better understand the preventive 
measures and treatments that are available for liver cancer, which include cancer 
screening and antiviral treatment for the high-risk populations, and curative cancer-
directed surgery for patients with liver cancer. There are three specific aims pursued as 
part of this dissertation: 
 
Aim 1: To investigate HCC screening practice among high-risk Chinese patients, to 
identify the sociodemographic and clinical factors related to HCC screening practice, to 
examine the association of sociodemographic and clinical factors with HCC screening 
knowledge level, and to identify the perceived barriers to HCC screening. 
 
Aim 2: To determine rates of medication adherence to NUC antiviral therapy among 
Chinese patients with chronic HBV using the Morisky Medication Adherence scale, to 
identify the self-perceived barriers to NUC adherence, and to investigate the impact of 
sociodemographic and clinical factors, treatment-related factors, and perceptions of 
disease on NUC adherence.  
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Aim 3: To identify the demographic and clinical factors associated with delay in HCC 
surgical treatment, and to evaluate the association of surgical delay and long-term survival 
in HCC patients, using records queried from the Commission on Cancer’s National Cancer 
Database. 
 
The findings of these studies will contribute to the increase of knowledge on the adherence 
and self-identified barriers to disease management and HCC prevention among patients 
chronically infected with viral hepatitis. We will also acquire a better understanding about 
the relationship of surgical treatment delay or prolonged surgical wait-time and cancer 
survival in HCC patients. These results are expected to have a significant and positive 
impact on promoting cancer prevention in patients with chronic viral hepatitis and timely 
treatment for patients with HCC. The study findings could ultimately serve to reduce the 
likelihood of developing HCC among the high-risk patients, and increase the chances of 
survival among those who have already developed HCC. 
 
Hepatocellular Carcinoma Overview  
Epidemiology of HCC  
Liver cancer is the sixth most common malignancy worldwide, but it is the second-
leading cause of cancer death, representing roughly 9.1% of all cancer mortality. Globally, 
liver cancer is the fifth most common cancer in males and seventh in female [2], and HCC 
accounts for the majority (~85%) of primary cancer of the liver [3]. According to 2015 global 
estimates, there were an estimated 854,000 new cases and 810,000 deaths due to liver 
cancer [1]. Liver cancer has a higher prevalence in developing countries as most cases 
(~83%) are diagnosed in less developed nations [20]. It is the third most common cancer 
in developing countries among men, following lung and stomach cancer [21]. Liver cancer, 
in particular, places a huge burden on the Chinese population. China alone accounts for 
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approximately 50% of the total number of liver cancer cases and deaths globally [4]. 
Moreover, liver cancer is identified as the second leading cause of cancer death among 
males and third among females in China [4]. In terms of economic burden, using the 
Chinese hospital information database that consisted of 350 million inpatient records, in 
year of 2015, total health care expense for liver cancer treatment was 10.2 billion RMB. 
This was only ranked behind treatment for cancers of the lung (24.3 billion), colon and 
rectum (20.8 billion), stomach (15.7 billion), breast (11.5 billion) and cervix (11.5 billion) 
[22]. In addition to causing major health issues in China, in the United States, liver cancer 
is one of the fastest growing causes of cancer-related death [11]. According to 2017 
estimates, there were 40,710 newly diagnosed cases and 28,920 associated deaths of 
liver cancer in the U.S. [23]. 
 
Risk factors of HCC 
 The major risk factors for developing HCC are infection with HBV or HCV, chronic 
alcohol consumption, aflatoxin exposure, and non-alcoholic fatty liver disease potentially 
associated with diabetes and obesity [3]. Nearly 50% of all cases of HCC in the world are 
associated with HBV infection, while 25% of HCC cases are associated with HCV infection 
[24]. Genetic risk factors include hereditary hemochromatosis, primary biliary cirrhosis, 
autoimmune hepatitis, alpha 1-antitrypsin deficiency syndrome, and Wilson’s disease [25]. 
Obesity and diabetes mellitus are also known to be highly correlated with increased risk 
for HCC [26]. In terms of environmental factors, chronic aflatoxin exposure is highly 
associated with HCC as it can damage the DNA of hepatic cells [27]. Moreover, study has 
found that due to synergistic effect, aflatoxin exposure increases the risk for HCC 
progression when combined with HBV infection [28]. Aflatoxin is a mycotoxin that 
contaminates stored foods, including corn, rice, soybeans and peanuts. Aflatoxin poses 
as a more serious risk factor in people from Asian and African countries [28].  
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Secondary Prevention for Hepatocellular Carcinoma  
HCC screening 
As liver cancer is a major disease burden, it is crucial to detect it in its early stage 
so that timely treatments could be offered. Detection by routine screening is the best way 
to improve survival and to achieve better prognosis. Commonly used screening tools 
include serum alpha-fetoprotein (AFP), abdominal ultrasound, or a combination of both 
tests [29]. Several guidelines on HCC surveillance have been published and updated 
globally.  A comparison of HCC screening guidelines developed and published by different 
professional societies can be found in Appendix A. The combination of serum AFP and 
ultrasound at 6-month intervals is the standard liver cancer screening method 
recommended by the Asian Pacific Association for the Study of Liver (APASL) for 
populations with high risk of developing liver cancer [30]. The high-risk populations for 
developing HCC are patients with HBV infection, HCV infection, HBV and HCV coinfection, 
cirrhosis, diabetes mellitus, and those with severe alcohol abuse or a family history of 
HCC [31].  
The clinical effectiveness of AFP has been demonstrated with randomized 
controlled trials that involved more than 18,000 patients with a history of chronic hepatitis 
or HBV infection, and the findings have indicated that biannual screening with AFP and 
ultrasound reduced mortality by 37% [32]. In addition, several other studies have reported 
screening to be cost-effective and effectual in reducing mortality in populations with HCV 
infection and cirrhosis [33-35]. On the other hand, the liver cancer screening guidelines 
developed by the American Association for the Study of Liver Diseases (AASLD) 
recommend that patients with liver cirrhosis to undergo screening at 6-month intervals with 
only ultrasound [36]. Studies have shown that AFP lacks efficacy as a surveillance test for 
liver cancer, with an inadequate sensitivity and specificity at 66% and 82%, respectively 
[37]. Comparatively, ultrasound was reported to have a sensitivity of between 65% to 80%, 
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and a specificity greater than 90% [38]. In addition, combined usage of ultrasound and 
AFP can increase detection rates, but may increase false-positive rates and screening 
costs. Employing only ultrasound has been indicated to have a 2.9% false-positive rate, 
whereas the combination resulted in a 7.5% false-positive rate [39]. Although 
disagreement exists for the application of AFP in liver cancer screening, both the APASL 
and AASLD guidelines recommend screening at timely intervals of every 6 months for 
high-risk populations.  
 
Theoretical framework of barriers and facilitators for HCC screening 
As shown in Figure 2, the framework that links the barriers and risk factors for HCC 
screening is modified from the Health Belief Model [40]. The Health Belief Model was 
developed in the early 1950s in order to understand the failure of populations to adopt 
disease prevention measures or screening tests for early disease detection [40]. The 
Health Belief Model emphasizes the theory that behaviors mainly depend upon the value 
placed by an individual on a specific goal and the individual’s estimate of likelihood that 
the action performed would achieve this goal [40]; this theory closely ties with the 
dissertation study. When perceived barriers outweigh perceived benefits, the likelihood of 
taking the recommended preventative health action decreases, leading to noncompliance 
or a lack of adherence. In addition, an individual’s modifying factors can have an impact 
on perceived susceptibility, perceived severity, perceived benefits, as well as perceived 
threat. For instance, high-risk patients with cirrhosis are more likely to have higher level of 
perceived severity and perceived threat compared to those without cirrhosis; therefore, 
cirrhotic high-risk patients are more likely to undergo routine HCC screening due to a 
greater level of perceived benefit.  
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Figure 1. Theoretical framework of barriers and facilitators for HCC screening; 
adapted from Health Belief Model, Janz & Becker, 1984 [40]. 
 
Knowledge and barriers to HCC screening 
 As HCC screening has been demonstrated to improve early cancer detection and 
increase the chance for receiving curative treatments, which would ultimately result in 
more optimal long-term survival [32], adherence to recommended bi-annual cancer 
Modifying factors  
Age, gender, region of 
residency, education, income, 
insurance, family history, 
hepatitis infection history, 
cirrhosis status, comorbidity, 
liver cancer knowledge  
 
Perceived benefits 
Early diagnosis leads to 
early treatment; HCC is 
potentially curable in early 
stage 
 
Perceived susceptibility 
Individuals with cirrhosis 
or chronic hepatitis are at 
increased risk for 
developing HCC 
 
Perceived severity 
HCC yields poor prognosis 
 
Cues to action 
-Education provided from physicians 
-Education provided from community 
health promotion workers 
-Reminders from healthcare 
providers 
-Undergoing screening due to 
personal experiences 
-Knowing someone with HCC 
-Trust in HCC screening tests 
 
 
Perceived barriers 
-Not aware that screening exists 
-No symptoms or discomfort 
-Lack of physician recommendation 
-Do not know the screening benefits 
-Why bother screening if it is hard to 
treat 
-Financial difficulty 
-Afraid of HCC detection 
-Lack time 
-Access difficulty 
-Screening is not effective 
-Not afraid to develop HCC 
 
 
 
 
Perceived threat 
from HCC 
Likelihood of behavior 
change when 
perceived benefits 
outweigh perceived 
barriers 
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screening is critical for HCC prevention. In order to develop and implement effective 
interventions to improve HCC surveillance rates, there is a need to better understand and 
characterize patient-level knowledge, attitudes and perceived barriers regarding HCC 
screening. There is currently limited research conducted in the U.S., Taiwan, and China 
that investigated the knowledge, awareness and perceptions on HCC surveillance [6, 8, 
41]. Farvardin et al. surveyed 541 cirrhotic patients to determine patient reported factors 
related to HCC surveillance in a racially diverse and socioeconomically disadvantaged 
cohort of patients of a hospital in Dallas, Texas [41]. Patients were identified using a 
validated set of ICD-9 codes for liver cirrhosis, and eligible participants were recruited to 
complete a survey at the time of clinic appointment or by telephone. The survey consisted 
of four sections, which included knowledge on HCC, potential barriers to HCC surveillance 
completion, patient attitudes, and demographic information. The primary outcome was the 
receipt of abdominal imaging for surveillance purposes within a 12-month period 
preceding and 6-month period after administration of the survey. The findings indicated 
that patients had an overall high level of HCC-related knowledge; however, interestingly, 
48.6% considered that eating a healthy diet would preclude them from having to undergo 
bi-annual HCC screening. Moreover, 34.0% indicated that HCC surveillance would not be 
necessary with normal physical exams or without the presentation of clinical symptoms. 
Of the 49.9% of patients who reported to have barriers for receiving HCC screening, the 
most common reasons included “difficulty with the scheduling process” (30.5%), “costs of 
surveillance testing” (25.3%), and “transportation difficulties” (17.3%). Furthermore, 
patients who received HCC screening were 3.1 times more likely to acknowledge that 
cirrhosis was a risk factor for HCC development [41].  
A cross-sectional study carried out in an outpatient clinic of a medical center in 
Taiwan utilized two structured questionnaires to measure the patient perceptions on HCC 
prevention and knowledge regarding viral hepatitis and liver cancer [8]. A total of 400 
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patients with chronic HBV and/or HCV were recruited, and the questionnaires were 
designed based on concepts of the health belief model. The scale for perceptions on HCC 
prevention comprised 34 questions concerning perceived susceptibility, perceived 
severity, perceived benefits, perceived barriers, and cues to action. The scale for liver 
cancer and hepatitis infection knowledge had 15 questions on topics that included liver 
function, blood tests for hepatitis, hepatitis symptoms, modes of viral transmission, and 
liver cancer screening. The researchers found that older patients, as well as those with 
lower socioeconomic status, were more likely to have negative perceptions and had a 
lower knowledge score. In the multivariable analysis, participants’ age and perceived 
barriers were significantly associated with a willingness to undertake antiviral treatment 
[8].  
Moreover, it has been reported that there is a lack of awareness for HCC 
prevention and surveillance among the general Chinese population. A survey study was 
conducted among 1,300 participants within the inpatient unit of a tertiary hospital in 
Southern China to assess the level of an inpatient population’s awareness and knowledge 
about hepatitis infection and primary liver cancer [6]. The 51-item structured questionnaire 
contained questions on sociodemographics, and knowledge regarding route of HBV 
transmission, risk factors of HCC, symptoms and signs of HCC, preventive methods of 
HCC, and management and treatments for HCC. The investigators reported that 
participants’ level of education had the biggest impact on their total knowledge score, while 
other factors including occupation, income, and any known history of cancer within families 
had less impact [6].  
 
Hepatocellular Carcinoma Prevention through Management of Chronic Hepatitis 
due to HBV Infection 
23 
 
 
 
 As discussed previously, approximately 50% of all HCC cases in the world are 
associated with HBV infection. It has been reported that the risk of developing HCC is 100 
times greater among patients infected with HBV compared to those without the infection, 
and the risk becomes even greater for patients with both HBV and cirrhosis [36]. In terms 
of the mechanism of which HBV infection causes HCC, it is believed that HBV could be 
directly oncogenic by incorporating itself into a host genetic material, where the HBV DNA 
is integrated into chromosomes of the hepatocytes and serves as a precursor to HCC [42]. 
Another suggested mechanism of HBV-induced HCC is due to an indirect effect; this can 
be achieved through the process of inflammation, regeneration, and cirrhosis due to HBV 
infection [42]. According to World Health Organization (WHO), about 5% of healthy adults 
infected with HBV will develop chronic infection [43]. Among chronically infected patients, 
approximately 20-30% will eventually go on to develop cirrhosis or liver cancer [43]. A 
study has reported that after being infected with HBV, it takes roughly 10 years to develop 
chronic hepatitis; 20 years to develop cirrhosis and 30 years to develop HCC [44]. 
Although most HBV-infected patients who develop HCC also have cirrhosis (70-90%), 
HBV can directly cause HCC without cirrhosis [45].  
Although the incidence of HBV-associated HCC has decreased in the past few 
decades, HBV is still responsible for nearly half of HCC cases globally [24]. To prevent 
the development of HCC, it is of importance to implement effective preventive measures 
to control and to manage HBV infection from further progression or deterioration. Such 
preventive methods include widely promoting the HBV vaccine to immunize against the 
virus [49, 50], undertaking recommended bi-annual HCC screening with ultrasound and 
AFP, and undergoing nucleot(s)ide analogs antiviral therapy.  
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Figure 2. Natural course of HBV disease progression; adapted from Sundaram & Kowdley, 
2015 [46]. 
 
Epidemiology of HBV infection in China 
In China, chronic HBV infection is the leading cause for developing HCC [47]. 
Globally, China is the nation with a high prevalence of HBV infection, as approximately 
one-third of the total populations who are chronically infected with HBV are residing in 
China [5]. According to a national sero-epidemiological survey conducted in 1992, 
approximately 120 million people in China were infected with HBV [47]. Since chronic HBV 
is a major health concern in China, the universal vaccination program for infants started 
in 1992 has played an important role in changing the epidemiology of HBV infection in 
China from highly to moderately endemic [9]. Yet, the timely dose of HBV vaccine 
coverage is lower in the economically disadvantaged western and middle provinces than 
the eastern provinces of China [48]. Moreover, immunization coverage is lower in rural 
than in urban areas [49]. As HBV infection imposes considerable economic burden on the 
infected patients and their families, and is responsible as a major national healthcare 
spending [22], with a current 93 million HBV carriers and chronic HBV patients, HBV 
infection remains a major issue in China [50].  
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Nucleo(t)ide analogues therapy for chronic HBV 
Among patients chronically infected with HBV, antiviral therapy plays an important 
role in controlling the infection by slowing down disease progression to cirrhosis and liver 
cancer [51]. There are two major groups of antiviral agents approved for the treatment of 
chronic HBV. These are known as immunomodulatory agents, which include conventional 
interferon alpha (IFN-α) and pegylated interferon alpha (PEG-IFNα), and five oral 
nucleot(s)ide analogs (NUCs). The advantages associated with interferon-based therapy 
consist of the lack of drug resistance and the finite duration of therapy. Nevertheless, a 
large number of patients do not respond to this treatment and would still require long-term 
management using NUCs [52]. The NUCs approved to be used as antiviral therapy include 
lamivudine, telbivudine, entecavir, adefovir, and tenofovir [53]. NUCs target the HBV 
polymerase, which is a multifunctional protein that is essential for viral replication. The 
main function of NUCs is to eradicate HBV from the host. NUCs act by direct inhibition, 
through acting as chain terminators by incorporating it into the viral DNA or through 
competitive binding with the endogenous substrates [51]. While completely eradicating 
HBV may be unlikely with antiviral therapy, NUCs serve to prevent the development of 
cirrhosis, decompensated liver diseases and HCC [51]. Prolonged antiviral treatment 
using NUCs has shown to improve liver histology by effectively reducing the grades of 
inflammation and by reversal of liver cirrhosis [51].  
 
HBV antiviral therapy in China 
Five NUCs, conventional IFN-α, and two formulations of PEG-IFNα have been 
approved for treating chronic HBV infection in China [54]. Based on guidelines established 
by the Chinese Society of Hepatology and Chinese Society of Infectious Diseases, all 
NUCs are recommended as first-choice treatments [55]. On the other hand, according to 
the AASLD and several international guidelines, entecavir and tenofovir are 
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recommended as the first-line of NUC therapy in the treatment of chronic HBV [56, 57]. 
Although randomized clinical trials have demonstrated that entecavir and tenofovir have 
low incidence of drug resistance and a potent antiviral effect [54], due to the high costs of 
these medications and inadequate medical insurance coverage, entecavir and tenofovir 
are not affordable or reimbursable for many Chinese patients. Therefore, low-to-moderate 
generic barrier drugs, including lamivudine, telbivudine, and adefovir dipivoxil are still 
commonly used in China [9, 10]. Based on the average annual income of people from the 
general Chinese population, entecavir and PEG-IFNα produced by foreign pharmaceutical 
companies are very costly and are often only covered by a small proportion of health 
insurance [54]. By using less costly drugs, the healthcare system reduces the cost for 
treatment in the short term; however, medical expenses may increase in the long run as 
some patients will develop suboptimal response and drug resistance [54]. 
 
Adherence and barriers to HBV antiviral therapy  
Adherence to antiviral treatment is fundamental in the optimal clinical management 
of patients with chronic HBV, and the majority of patients with chronic HBV require long-
term and possibly lifelong treatment. As of this date, there are a limited number of studies 
that utilized questionnaires to investigate the adherence to HBV antiviral treatment and 
the factors associated with adherence in the U.S., Australia, and the Netherlands [58-60]. 
Chotiyaputta et al. recruited 111 patients with chronic HBV who were receiving NUC from 
the University of Michigan Health Clinics, U.S. [58], and the participants were asked to 
complete a survey every 3 months for up to one year. Adherence rate was defined as the 
percentage of days patients took their HBV medications during the last 30 days, and 
virological response was evaluated by monitoring serum HBV DNA every 3-6 months. The 
medical records of patients were reviewed to retrieve information on medical history, 
current and previous HBV treatments, and virological response. The investigators found 
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that 69 patients (74.1%) reported a 100% adherence using the survey, and patients with 
100% adherence were significantly older, more likely to be male, and had higher annual 
household income compared to those without 100% adherence. The most common 
reasons for missing HBV medication(s) during the past 30 days were attributed to 
“forgetfulness” and “travelling away from home”. Chotiyaputta and colleagues also noted 
that self-reporting of adherence to healthcare providers was inflated as 78 patients (83.9%) 
reported 100% adherence to their healthcare providers. Additionally, patients with better 
adherence to NUC treatment had a trend towards lower rate of virological breakthroughs 
[58].   
Giang and colleagues from Australia also assessed the adherence rates to NUC 
therapy in patients with chronic HBV infection and evaluated the factors associated with 
non-adherence [59]. This study was conducted in the liver clinics of a hospital in Australia, 
and a total of 80 patients who were taking one or more NUCs were asked to complete a 
32-item questionnaire. The patients were asked to rate their overall adherence to NUCs, 
other prescription medications (if any), and scheduled appointments using visual analogue 
scales that ranged from 1 to 10. A score of 1 indicated poor adherence or that they 
frequently skipped taking NUCs/other prescription/appointments. On the other hand, 
score of 10 meant that adherence was excellent and patients fulfilled these criteria 100% 
of the time. The researchers reported that 49 patients (66%) had optimal adherence and 
that 34 patients (43%) had omitted taking their NUCs sometime in the past. Of patients 
who reported skipping medications, “forgetfulness” (56.3%), “ran out of medications” 
(10.4%) and “a change in daily routine” (10.4%) were cited as the most common reasons 
In addition, patients who reported low adherence to other prescription drugs were more 
likely to skip NUCs, and patients who were cared by a language-discordant clinician were 
more likely to have suboptimal adherence [59].  
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 A prospective study was conducted in the Netherlands to investigate adherence to 
entecavir among 100 chronic HBV patients visiting the outpatient clinics of two academic 
hospitals [60]. The participants were given medication dispenser that monitored entecavir 
intake during the 16-week therapy period. HBV DNA was measured at the baseline and 
after 16 weeks, and patients’ beliefs about medicine (assessed using the Beliefs About 
Medicines Questionnaire (BMQ)), self-reported adherence (evaluated using the 
Medication Adherence Report Scale (MARS)), as well as experiences regarding the 
Sensemedic system (the Sensemedic medication dispenser monitors medication intake 
real-time) were examined using a follow-up questionnaire. The primary endpoint was 
adherence during 16 weeks, and adherence was calculated using the formula of (number 
of treatment days – number of missed doses)/ number of treatment days. Adherence over 
a 16-week period averaged 85%, with 70% of patients exhibiting good adherence (≥80%), 
and 52% of patients measured to have at least 90% adherence. Patients with poor 
adherence were significantly younger and had more indifferent attitudes towards entecavir. 
Additionally, the investigators reported that they did not observe poor adherence to be 
independently associated with virological response [60]. 
 
Tertiary Prevention for Hepatocellular Carcinoma 
Surgical treatment options 
Although there are a number of available prevention and control measures for HCC, 
unfortunately, a large number of the high-risk patients with chronic viral hepatitis or 
cirrhosis will eventually develop the disease and would therefore seek to receive curative 
HCC treatments. According to reports published by the American Cancer Society, The 
detrimental effect of liver cancer is indicated by its low survival rate, with 5-year relative 
survival rates at 31%, 11% and 3%, respectively, for stages of localized, regional and 
distant [61]. One of the main reasons for the low survival rate is that most patients are 
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diagnosed with liver cancer during the advanced stage, which cannot be curatively treated 
and can only be provided with palliative treatment to relieve pain [62]. While certain 
cancers may respond to adjuvant chemotherapy or radiation, neither chemotherapy nor 
radiation for late-stage liver cancer reduces mortality rates. Nevertheless, there are 
effective treatments during the early stage, which include surgically removing part of the 
liver, local ablation of small lesions, and liver transplantation [29]. While the majority of 
patients diagnosed with liver cancer in the early stage survive for more than 5 years, those 
diagnosed in advanced stage usually survive for less than a year [62]. Moreover, survival 
rates are often higher in patients who receive surgical treatments to remove the tumor, 
regardless of stage, whereas untreated patients with advanced disease often survive for 
less than 6 months [63].  
 
Loco-regional therapies  
Surgical resection and liver transplantation are the first line of treatment choices 
with early stage tumors; however, resection can only be performed on a small proportion 
of patients at the time of diagnosis (often due to compromised liver function) and there is 
a shortage of liver donors for transplantation [64]. Therefore, locoregional therapies, which 
are potentially curative treatments, are often offered to slow the advancement of disease 
for patients waiting on transplantation [65]. Local ablative therapy is classified into two 
groups: chemical ablation and thermal ablation [66]. Chemical ablation involves using 
substances such as ethanol and acetic acid, while thermal ablation utilizes microwaves, 
cryoablation, lasers, and radiofrequency [66]. Radiofrequency ablation (RFA) is the most 
effective and a widely used local ablative method; it is also one of the best alternative 
treatments for patients with early-stage HCC who are unable to receive resection or 
transplantation. RFA is less invasive, less expensive, and has shown to have lower 
complication rates and shorter length of stage than resection [67]. Percutaneous ethanol 
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injection (PEI) can be used as an alternative therapy for small HCC tumors in patients who 
are considered poor candidates for resection [68]. Furthermore, transarterial 
chemoembolization (TACE) serves to manage multifocal HCC and tumors that are 
unresectable to downstage lesions before transplantation takes place [36]; TACE is an 
effective approach for intermediate-stage HCC.  
 
Surgical resection 
 Hepatic resection is recommended to patients with preserved liver function and 
with early stage tumor. Resection is considered ideal for patients with maintained hepatic 
reserve, such as patients with single lesions and without evidence of vascular invasion 
[69]. Since resection increases the risk of hepatic decompensation for patients with 
cirrhosis, only those with Child-Pugh class A and well-compensated cirrhosis are 
considered as candidates [66]. Compared to local-regional therapy, resection allows a 
complete pathological analysis of the cancerous sample [68]. Although resection is 
considered curative and that resected patients have five-year survival as high as 70%, 
recurrence is still common [70]. The prognosis of resected patients is most heavily 
influenced by tumor recurrence, and other factors such as tumor size, liver function, tumor 
nodules, and portal pressure [71, 72]. 
 
Liver transplantation 
 Liver transplantation for HCC is considered the best treatment option for early-
stage tumors, and it accounts for approximately 30% to 40% of all liver transplantations 
[73]. Since transplantation deals with both the tumor and underlying liver disease, patients 
who receive transplantation have the best chance of a cure compared to other treatments 
[74]. Due to the worldwide liver shortage, not all HCC patients who are candidates for 
transplantation are able to receive this procedure, and physicians are selecting patients 
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with the most survival benefit after transplantation to efficiently use the scarce source of 
liver grafts. Currently, the Milan criteria are the most widely used criteria (single tumor ≤5 
cm or three tumors all ≤3 cm), and have shown to result in a 5-year survival rate of 75% 
with tumor recurrence rate less than 15% [75-77]. In terms of organ allocation, the Model 
for End-Stage Liver Disease (MELD), adopted by the United Network for Organ Sharing 
(UNOS), is a popularly accepted allocation policy/system that serves to decrease waiting 
time and drop-out rates. The MELD score accesses severity, and follows the principle of 
allocating organs to patients who are at the highest risk of death during their wait time [78]. 
A downside of the MELD score is that it is not able to predict mortality among HCC patients; 
thus, allocation system gives exemption points to HCC patients (which is allocated 6 
months after listing) on the basis of tumor burden to equalize the risk of death [73]. 
 
Impact of surgical treatment delay on HCC outcomes 
Due to the poor survival of HCC patients and that majority of the patients are not 
eligible for curative treatment, it is necessary to initiate early therapy once a diagnosis has 
been confirmed. Currently, there are no established guidelines for defining delay in HCC-
directed surgery or the optimal time interval from diagnosis to surgery. Several studies 
have investigated the clinical impact of HCC therapeutic delays or prolonged wait time on 
patient outcomes, and results have been largely inconsistent [13-19]. A total of three 
studies have investigated the survival impact of delayed locoregional therapies among 
HCC patients in Taiwan [14, 15] and Canada [16], and all found that wait time was 
associated with an increased risk of mortality [14-16]. A study in Taiwan conducted by Huo 
and colleagues consisted of 144 Taiwanese patients with HCC who underwent 
chemoembolization, percutaneous ethanol or acetic acid injection from 1998 to 2003 [14]. 
Delay was determined as >2 months between diagnosis to treatment, and survival rates 
were compared between 48 patients with treatment delay versus 96 gender- and age-
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matched controls without delay. It was found that delayed HCC treatment was linked with 
shortened overall survival [14]. Another study also conducted in Taiwan included 121 HCC 
patients detected through a surveillance program who underwent RFA as the initial 
treatment modality, and delayed surgery was defined as >5 weeks starting from diagnosis 
[15]. The researchers found that a longer wait time was an independent predictor of poorer 
survival [15]. Similarly, Brahmania et al. from Canada found that incremental 30-day wait 
periods were associated with a 9% increased risk of residual tumor (HR: 1.09) and 23% 
increased risk of death (HR: 1.23) [16]. In this study, the sample comprised 219 HCC 
patients diagnosed between 2010 and 2013 in the University Health Network in Toronto. 
All patients received curative intent RFA for HCC, and wait time was defined using 30-day 
increments [16].  
In addition to locoregional therapies, investigators have also evaluated the impact 
of wait time on HCC outcomes in hepatic resection. One study conducted in Boston, U.S. 
included 350 patients with various primary hepatobiliary tumors, and delay was considered 
as >1 month from presentation until surgical referral [17]. The investigators observed that 
delays adversely affected survival in resected patients. However, the results of this study 
should be reviewed with caution as HCC only represented 24% of the primary liver tumors; 
there is no comparison of tumor stage and analysis was not conducted for different types 
of liver tumors [17]. A 2017 study published in Journal of Hepatology reported that delay 
for ≥3 months from diagnosis to resection did not affect oncological recurrence and 
survival outcomes [18]. This study was conducted prospectively from 2006 to 2016 in a 
tertiary medical center in France to evaluate the impact of time to resection after diagnosis 
on recurrence rate, recurrence-free survival, and intention-to-treat overall survival. The 
study consisted of 100 patients who consecutively underwent curative-intent resection for 
BCLC 0-A HCC, and multivariable analyses indicated that there was no statistically 
significant difference for tumor recurrence rate (32% vs. 32%, P=1.0), recurrence-free 
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survival (37% vs. 48%, P=0.42), and 5-year overall survival (82% vs. 80%, P=0.20) [18]. 
Thus far, this has been the only study that did not observe a statistically significant 
relationship between wait time to HCC-directed surgery and long-term outcomes. 
Additionally, a few other studies conducted in the U.S. have investigated the same 
topic while combining HCC patients who received different types of treatment modalities 
or cancer care, and analyzed them altogether [13, 19]. A retrospective cohort study was 
conducted among 267 cirrhotic patients diagnosed with HCC in hospital in Dallas, Texas 
between 2005 and 2012 [13]. Information on demographics, clinical history, laboratory 
data, and dates of HCC diagnosis and treatment initiation were abstracted from medical 
records. HCC treatments included liver transplantation, resection, RFA, 
chemoembolization, systemic chemotherapy, and supportive care. The researchers 
reported that using a treatment delay cutoff at 3 months, therapeutic delay led to worse 
prognosis [13]. On the other hand, a study conducted in the U.S. Department of Veterans 
Affairs (VA) found that delay of 60 days from diagnosis to treatment was associated with 
a decreased risk of death among VA patients treated with curative surgery, liver-directed 
therapy, or chemotherapy for BCLC stage C HCC (HR: 0.50; 95% CI: 0.37–0.67) [19]. As 
shown from the literature review, research on this topic has produced inconsistent findings, 
and results of the majority of these studies were based on relatively small samples [13-
19].  
 
Knowledge gaps  
Gap 1. Knowledge, awareness and perceived barriers to hepatocellular carcinoma 
screening in high-risk Chinese patients. 
To prevent high-risk patients with liver cirrhosis, chronic HBV or chronic HCV from 
developing HCC, it is of crucial significance to understand the current practice for HCC 
screening in China. Routine screening is known as the best way to detect early-stage HCC 
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and improve cancer survival and prognosis [29, 80]. Currently, there is limited literature 
that examined the knowledge level, attitudes and self-reported barriers for undergoing 
recommended HCC screening [8, 41]. Furthermore, although no population-based data 
have been published about HCC screening rates in China, studies have suggested that 
screening rate is low or less than optimal due to a lack of knowledge and awareness 
among the general Chinese population and even among healthcare workers [6, 7]. In a 
study that included Chinese public health workers in Hangzhou, Zhejiang province, 29% 
were not aware that chronic HBV infection was a major risk factor for cirrhosis and liver 
cancer, and 30% did not know about the importance of HBV vaccine [7]. Since screening 
serves to detect HCC at an earlier stage, effective treatments could be offered to achieve 
better chance of survival. As healthcare professionals recommend HCC screening for the 
at-risk patients, it is essential to identify the self-identified barriers that hinder HCC 
screening so that more effective approaches could be implemented to promote screening 
for early cancer detection. Furthermore, it would also be of importance to identify the types 
of patients who are less compliant to screening, so that preventive measures could 
potentially target these populations. Therefore, to address these gaps, we propose to 
investigate the practice, knowledge and perceived barriers to HCC screening in high-risk 
Chinese patients (Aim 1). 
 
Gap 2. Adherence rates and self-reported perceived barriers to NUC antiviral 
therapy in Chinese patients with chronic HBV. 
 In managing patients with chronic HBV, antiviral therapy functions to slow down 
and reverse disease progression, which serves to reduce the risk of developing cirrhosis, 
liver failure and liver cancer. While a few studies have utilized questionnaires to investigate 
the adherence to HBV antiviral treatment [58-60]; the studies were limited to relatively 
small sample sizes. Research conducted by Chotiyaputta et al. consisted of 111 patients 
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recruited from the University of Michigan Health Clinics [58], while Giang et al. and van 
Vlerken et al. enrolled 80 and 100 participants [59, 60], respectively. In study carried out 
in Australia, Giang and colleagues found that 74.1% of patients reported an adherence 
rate of 100% [59], while 66% and 52% of patients from studies conducted in the U.S. and 
the Netherlands were measured to have adherence rate of 90% [58, 60]. In addition to the 
lack of sample size, there is a dearth of research focused to assess the self-perceived 
barriers and facilitators for adherence to HBV antiviral therapy. Since China has a high 
prevalence of chronic HBV infection, it is crucial to understand the obstacles for 
undergoing HBV treatment using a validated instrument. Therefore, to have a more 
comprehensive understanding about antiviral therapy utilization and obstacles that affect 
HBV treatment, we propose to examine adherence rates and perceived barriers to NUC 
antiviral therapy in Chinese patients with chronic HBV (Aim 2). In addition to China, 
findings generated from this study may be utilized to develop strategic preventive 
measures to improve antiviral therapy compliance in other regions of world with high 
prevalence of HBV infections, including countries in East Asia, Southeast Asia and Sub-
Sahara Africa.  
 
Gap 3. Survival impact of surgical treatment delay on long-term outcomes in HCC 
patients.   
Among chronically infected patients with viral hepatitis, approximately 20-30% will 
eventually develop cirrhosis or HCC [47]. Once HCC diagnosis has been confirmed, there 
are a few potentially curative surgery options for patients in early stage, including liver 
transplantation, partial resection, and RFA. Due to the poor prognosis of HCC, it is 
necessary to initiate early active therapy once the disease is diagnosed. Currently, 
however, there are no established guidelines for defining surgical delay in HCC-directed 
surgery. Several studies have investigated the clinical impact of HCC therapeutic delays 
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or prolonged wait time on outcomes in patients who underwent locoregional therapies [14-
16], resection [17, 18], and with different treatments analyzed altogether [13, 19]. 
Nevertheless, most were restricted to single centers with limited sample sizes, ranging 
from 100 to 742 cases.  
Furthermore, the previous studies have produced inconsistent findings. The 
majority of research found that prolonged wait time to surgery was linked with shortened 
survival, including cases treated with loco-regional therapy and resection [13-17]. On the 
other hand, a study conducted among VA patients found that surgical delay, defined as 
60 days from diagnosis, was associated with a decreased risk of death [19]. Another study 
that evaluated the survival impact of time to surgery in 100 patients who underwent 
surgical resection for BCLC0-A HCC discovered that there was no association, and that a 
delay of 3 months did not affect oncological outcome [18]. Due to these conflicting 
observations, we propose to evaluate the association of surgical treatment delay and long-
term prognosis in HCC patients (Aim 3). In contrast to the majority of existing studies that 
utilized medical records, our retrospective analysis that is based on large comprehensive 
clinical data provides a different perspective. 
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PRACTICE, KNOWLEDGE AND BARRIERS FOR SCREENING OF 
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Abstract 
Background: hepatocellular carcinoma (HCC) is among the leading causes of 
cancer deaths in China. Considering its poor prognosis when diagnosed late, Chinese 
guidelines recommend biannual screening for HCC with abdominal ultrasound and serum 
alpha-fetoprotein (AFP) test for high-risk populations.  
Objectives: To investigate the practice, knowledge and self-perceived barriers for 
HCC screening among high-risk hospital patients in China. 
Methods: An interview-based questionnaire was conducted among Chinese 
patients with liver cirrhosis, chronic hepatitis B and/or chronic hepatitis C infection from 
outpatient clinics at two tertiary medical institutions in Shanghai and Wuhan, China.  
Results: Among 352 participating patients, 50.0% had routine screening, 23.3% 
had irregular screening and 26.7% had incomplete or no screening. Significant 
determinants for screening included higher level of education, underlying liver cirrhosis, a 
family history of HCC, and better knowledge concerning viral hepatitis, HCC, and HCC 
screening guidelines. Moreover, factors associated with better knowledge were younger 
38 
 
 
 
age, female gender, urban residency, education level of college or above, annual 
household income of greater than 150K RMB, and longer duration of hepatitis infection. 
The three most frequent barriers reported for not receiving screening were not aware that 
screening for HCC exists (41.5%), no symptoms or discomfort (38.3%), and lack of 
recommendation from physicians (31.9%). 
Conclusions: Healthcare professionals and community leaders should actively 
inform patients regarding the benefits of HCC screening through design of educational 
programs. Such interventions are expected to increase knowledge about HCC and HCC 
screening, as well as improve screening adherence and earlier diagnosis. 
 
Introduction 
HCC is a primary malignant neoplasm accounting for 85-90% of primary liver 
cancer, which is the sixth most common cancer and the second-leading cause of cancer 
death worldwide [4, 79]. Liver cancer places a huge burden on the Chinese population. 
China alone accounts for approximately 50% of the total number of liver cancer cases and 
deaths globally [4]. In addition, liver cancer is identified as the second leading cause of 
cancer death among males and third among females in China [81]. In an effort to control 
and to reduce the detrimental effects of liver cancer in China, guidelines recommend the 
practice of screening for early cancer detection [32]. However, unlike in other East Asian 
regions, such as Japan, Korea and Taiwan, there is no government-funded nationwide 
HCC screening program for high-risk populations in China [82]. In China, the high-risk 
populations for developing HCC are patients with HBV infection, HCV infection, HBV and 
HCV coinfection, liver cirrhosis, diabetes mellitus, and those with severe alcohol abuse or 
a family history of HCC [31]. 
The detrimental effect of liver cancer is characterized by its poor prognosis, with 
5-year relative survival rate to be 10.1% in China [83]. Currently, there is no curative 
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treatment for the intermediate or advanced stage of HCC, and most patients are 
diagnosed during the advanced stage, which cannot be effectively treated [62]. While 
certain cancers may respond to adjuvant chemotherapy or radiation, neither 
chemotherapy nor radiation for late-stage HCC reduces mortality rates; nevertheless, 
treatments are more effective for early stage of HCC, which include surgically removing 
part of the liver, local ablation of small lesions and liver transplantation [29]. 
Routine screening is the best way to detect early-stage HCC and improve survival 
and prognosis [29]. The screening guidelines for HCC developed by the American 
Association for the Study of Liver Diseases (AASLD) recommend HCC screening every 6 
months for high-risk individuals by abdominal ultrasound [36]. On the other hand, 
screening guidelines published by the Peking University Medical Press and expert 
consensus established by the Chinese Anti-Cancer Association Society of Liver Cancer, 
Chinese Society of Clinical Oncology, and Chinese Society of Hepatology Liver Cancer 
Study Group recommend biannual screening with a combination of serum Alpha-
fetoprotein (AFP) and abdominal ultrasound at 6-month intervals for high-risk populations 
[31, 84]. The clinical effectiveness of AFP has been demonstrated in 18,816 patients with 
a history of chronic hepatitis or HBV infection, and findings indicated that biannual 
screening with AFP and ultrasound reduced mortality by 37% [32]. In addition, a 
combination of these two screening tests has been suggested as the most effective 
strategy for detecting HCC at an early stage, and complementary usage improved 
surveillance in patients with cirrhosis [85, 86]. 
While numerous studies have surveyed different populations to understand the 
knowledge and barriers for cervical, breast and colorectal cancer screenings, it is difficult 
to find similar studies conducted for HCC screening. Since healthcare professionals 
recommend HCC screening for the at-risk patients [79, 80], it is crucial to identify the 
barriers that hinder HCC screening so that more effective approaches can be implemented 
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to promote screening. Furthermore, since liver cancer is a major health concern in China 
and that China has a high number of HBV infected patients, it would be ideal to carry out 
this research study among Chinese patients. The main objectives of this study were to i) 
investigate HCC screening practice among high-risk Chinese patients, ii) identify the 
sociodemographic and clinical factors related to HCC screening practice, iii) examine the 
association of sociodemographic and clinical factors with HCC screening knowledge, and 
iv) identify the barriers to HCC screening. 
 
Methods 
Study Design and Data Collection 
This was a cross-sectional questionnaire study conducted from June to August 
2016 at the Shanghai Public Health Clinical Center of Shanghai and Hubei Third People’s 
Hospital of Wuhan, China. The source population were patients from outpatient clinics 
with a high risk of developing HCC, which comprised of patients with liver cirrhosis and 
patients with chronic HBV and/or HCV infection. Based on Chinese liver cancer screening 
recommendations, men aged 35 to 65 years and women aged 45 to 65 years were 
recruited.11 Patients diagnosed with the above conditions before 2015 were excluded from 
the study. Additionally, severely ill patients were not asked to participate.   
The questionnaire was designed by the study investigators based on hepatology 
experts’ opinions, and previous studies on the screening practices of cervical cancer, 
breast cancer and HBV infection [87-89]. In order to examine the feasibility and 
appropriateness of the questionnaire, a pilot test was conducted on 30 patients, with 15 
from each hospital. The official interviews took place after making adjustments of the initial 
questionnaire. Patients from outpatient clinics who met the eligibility criteria were 
introduced by their hepatologists to a trained interviewer. After informed consent was 
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obtained, an in-person interview was conducted in a private setting within the hospital. 
The questionnaire was anonymous and took an average of 10 minutes to complete. 
 
Measures and Assessment 
A total of 364 patients responded to the questionnaire and 12 had partial 
completions, which were excluded. The questionnaire consisted of three sections. Section 
One comprised of 11 multiple-choice and fill-in-the-blank questions, and the 
characteristics of interest were age, gender, current region of residence, household 
registration, education level, annual household income, health insurance, any immediate 
family member with HCC, duration of known hepatitis infection, cirrhosis status, and 
presence of comorbidity. Household registration, which classifies individuals as rural or 
urban residents, is a system of controlling population migration and determining eligibility 
for state-provided welfare and benefits [90]. There are three main types of insurance 
programs in China: Urban Employee’s Basic Medical Insurance (UEBMI) covers insurance 
for the urban working population, Urban Resident Basic Medical Insurance (URBMI) 
provides care to urban residents who are unemployed, and New Rural Cooperative 
Medical System (NCMS) provides financial subsidies for rural residents.  
The main outcome measure of the study was screening practice. Routine 
screening was defined as receiving both serum AFP and abdominal ultrasound at least 
every 6 months, irregular screening interval involved screening with both tests on an 
inconsistent interval, and patients with incomplete or no screening either never had AFP 
test or the combination of AFP and abdominal ultrasound. In section Two, patients were 
questioned if they have ever received AFP and abdominal ultrasound. If answered “yes”, 
patients were asked how often they received screening and the time of their most recent 
screening. If answered “no”, patients were asked to choose the reason (s) or barrier (s) 
for not having undergone screening and more than one choice were allowed. 
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Section Three consisted of 8 yes-or-no questions and 5 multiple-choice questions 
that examined the patients’ knowledge concerning viral hepatitis, HCC, and HCC 
screening guidelines. Two of the multiple-choice questions had 2 correct answer choices. 
The knowledge score (range: 0-15) was calculated by giving one point for each correct 
answer and zero points for an incorrect answer or an answer of “I do not know”. A copy of 
the questionnaire can be found in Appendix B.  
 
Statistical Analysis 
Data analysis was carried out with SAS 9.4 (SAS, Inc., Cary, NC), using 
significance level at P <0.05. Descriptive statistics were performed, and frequencies and 
percentages were reported for categorical variables while mean and standard deviation 
were presented for the continuous variable. Patients’ sociodemographic factors, clinical 
factors and knowledge were compared among the different screening practice groups 
using Chi-square or Fisher Exact test for categorical variables and one-way ANOVA for 
the continuous variable. All factors were included in a multinominal logistic regression 
model with stepwise model selection (P =0.15) to identify the independent predictors for 
screening practice. Adjusted odds ratio (OR) and 95% confidence intervals were 
generated for variables in the final model. 
 To investigate the association of knowledge with sociodemographic and clinical 
factors, t test, one-way ANOVA and Tukey post hoc test were utilized. In addition, multiple 
linear regression analysis was conducted with stepwise model selection (P =0.15) to 
examine the independent predictors for knowledge. Model diagnostics for regression were 
performed and data satisfied the assumptions in a linear regression model. There was no 
evidence of heteroscedasticity and missing covariates, and knowledge score 
demonstrated a normal distribution pattern individually and when combined with 
covariates. 
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This study was approved by the Institutional Review Board at the University of 
Nebraska Medical Center and the Ethics Committees of Shanghai Public Health Clinical 
Center and Hubei Third People’s Hospital.  
 
Results 
Patient Characteristics 
A total of 352 valid questionnaires were collected with a response rate of 92%. 156 
and 196 patients were recruited from Shanghai and Wuhan, respectively. The majority of 
patients were males (71.3%), currently resided in urban regions (85.8%), had urban 
household registration (77.6%) and UEBMI health insurance (67.9%), had no immediate 
relative diagnosed with HCC (78.7%) and were cirrhotic (62.8%). The mean knowledge 
score was 9.0 (SD: 2.8). A total of 176 patients (50.0%) had routine screening, 82 (23.3%) 
had irregular screening and 94 (26.7%) had incomplete or no screening. Out of the 94 
patients with incomplete or no screening, 83 had received ultrasound only and 11 never 
had either AFP or ultrasound. As shown in Table 1, screening practice was significantly 
associated with residence (P =0.003), household registration (P =0.003), education level 
(P <0.001), annual household income (P <0.001), family history (P =0.027), cirrhosis 
status (P =0.017) and knowledge score (P <0.001).  
 
Predictors of HCC Screening Practice  
Table 2 shows the results of multinominal logistic regression on factors associated 
with screening practice. Education level, family history, cirrhosis status and knowledge 
were significantly associated with screening practice. Patients with an education level of 
high school and college or above were 2.80 (P =0.002) and 3.94 (P =0.002) times more 
likely to receive routine screening, respectively, compared to patients graduated from 
middle school or below. Likewise, patients with a degree of high school and college or 
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above were 2.72 (P =0.005) and 2.62 (P =0.045) times more likely to receive irregular 
screening, respectively. Patients with an immediate family member with HCC were 2.86 
(P =0.011) times more likely to undergo routine screening and 2.51 (P =0.033) times more 
likely to receive irregular screening compared to patients with no family history with HCC. 
Additionally, cirrhotic patients were 2.39 times more likely to have routine screening 
compared to patients without cirrhosis (P =0.007). Knowledge was also a significant 
predictor; a one-point increase in knowledge score significantly increased the odds of 
undertaking routine screening (OR: 1.47; P <0.001) or screening with irregular interval 
(OR: 1.18; P =0.013). 
 
Factors Associated with HCC Screening Knowledge  
The association between sociodemographic and clinical characteristics with 
knowledge was generated from univariate analysis (Table 3). Patients from age group 35-
44 had better knowledge than patients aged 55-65 years (P =0.003). Patients living in 
urban areas (P <0.001) and patients with urban household registration (P <0.001) also 
exhibited better knowledge. Moreover, patients with a college education or above had 
better knowledge than patients with degrees of high school and middle school or below (P 
<0.001). Patients with an annual household income (RMB) of greater than 150K 
(approximately U.S. $22K) had better knowledge than patients who earned 40K-80K 
(approximately U.S. $6K-12K) and less than 40K (approximately U.S. $6K) (P <0.001). 
Additionally, patients with a hepatitis infection of 0-9 years had worse knowledge than 
patients with hepatitis infection for 10-19 years and 20 years or more (P <0.001). 
 
Predictors of HCC Screening Knowledge  
Table 4 illustrates the results of multiple linear regression on the significant 
predictors for knowledge. Patients aged 55-65 years and 45-54 years had knowledge 
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score of 1.49 point (P <0.001) and 0.98 point (P =0.010) lower than patients from age 
group of 35-44. Female patients scored 0.72 point higher in knowledge score compared 
to male patients (P =0.020), and patients living in rural areas had knowledge score of 1.25 
points lower than patients living in urban areas (P =0.002). In addition, patients with a 
college degree or above had 1.67 points higher in knowledge score than patients with a 
middle school degree or below (P <0.001). Patients with annual household income (RMB) 
of greater than 150K and 40K-80K scored 1.48 points (P =0.004) and 0.70 point (P =0.041) 
higher in knowledge score than patients who earned less than 40K. Furthermore, patients 
with a hepatitis infection of 20 years or more and 10-19 years had 1.59 points (P <0.001) 
and 0.92 point (P =0.007) higher in knowledge score than patients with hepatitis infection 
for 0-9 years. 
 
Specific Knowledge on Viral Hepatitis, HCC, and HCC Screening Guidelines 
Questions addressing knowledge are presented in Appendix A. The question with 
the highest percentage of overall correct response was “Is excessive alcohol consumption 
considered a risk factor for HCC?” (88.1%). The three questions with the lowest 
percentage of overall correct responses were “Does hepatitis have to cause cirrhosis 
before developing HCC?” (31.3%), “Prior to participation, did you know the purpose of the 
liver AFP test?” (39.8%), and “When should patients with chronic hepatitis start to undergo 
HCC screening?” (41.2%). As illustrated, patients with routine screening were most likely 
to answer each knowledge question correctly.   
 
Barriers to Participate in HCC Screening 
The frequencies of self-perceived barriers were analyzed and are described (Table 
5). The top five reasons for not receiving HCC screening were “Not aware that screening 
for HCC exists” (41.5%), “No symptoms or discomfort” (38.3%), “Lack of recommendation 
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from physicians” (31.9%), “Do not know the benefits of screening” (22.3%), and “Since 
HCC is difficult to treat, why bother to undergo screening” (18.1%). 
 
Discussion 
To our knowledge, this is the first study to evaluate the practice, knowledge and 
barriers for HCC screening among high-risk hospital patients in China. The results showed 
that only 50.0% of patients underwent standard routine screening. A meta-analysis 
involving 19 published studies on HCC surveillance adherence rate among 16,446 high-
risk patients found that the overall adherence was 61.0% [91]. This meta-analysis mainly 
comprised of studies from Europe and North America, and surveillance was defined as a 
combination of imaging plus AFP [91]. Moreover, retrospective studies on HCC 
surveillance conducted in East Asian regions, including Japan, Taiwan and Hong Kong, 
demonstrated that adherence rates varied from 15.2% to 79.0% among high-risk hospital 
patients [92]. 
 Similar to our findings, a study found that patients with degrees of high school or 
college or above had greater odds of undergoing routine screening. Moreover, a study 
that investigated the utilization of HCC surveillance among U.S. cirrhotic patients reported 
that patients with more than a high school education were more likely to receive regular 
HCC screening than patients with less than a high school education [93]. A study 
consisting of patients with chronic HBV, conducted in the San Francisco Bay Area and 
comprised of 92% Asian populations, found that patients with cirrhosis were more likely to 
have optimal HCC screening than patients without cirrhosis [94]. Furthermore, Zhao et al. 
found that cirrhotic patients had significantly higher surveillance adherence rates than 
patients with chronic HBV [91]. These results support our finding that cirrhosis was a 
significant determinant for receiving routine screening. Furthermore, patients with better 
knowledge concerning viral hepatitis, HCC, and screening guidelines were more likely to 
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be screened. Likewise, a survey that investigated HCC screening practice among San 
Francisco healthcare providers with large Asian American populations demonstrated that 
better knowledge concerning HCC and surveillance was associated with performing HCC 
screening [95]. 
 Our finding indicated that younger patients had better knowledge, and this is 
supported by a study conducted in chronic hepatitis patients in Taiwan, which found that 
patients’ age was negatively associated with hepatitis knowledge and health perceptions 
[8]. Moreover, our results demonstrated that residents residing in rural regions had worse 
knowledge, and this was even shown among Chinese healthcare and public health 
professionals, in which individuals from rural provinces had worse knowledge about HBV 
and liver cancer than those from urban provinces [7]. Studies conducted among hepatitis 
patients in Taiwan, general hospital patients in China, and cirrhotic patients at the 
University of Michigan have shown that education level was a major factor for 
demonstrating better knowledge in hepatitis and HCC [6, 8, 96]; these results are in 
accordance with our finding. Additionally, higher annual household income was an 
important factor on knowledge; Chen et al. discovered that household income was not 
only an important determinant on knowledge, but it was also positively corrected with 
perceived susceptibility, benefits, barriers and cues to action [8]. 
The knowledge question that was mostly missed was “Does hepatitis have to 
cause cirrhosis before developing HCC?”, as only 31.3% of the overall population and 
25.5% of patients with incomplete or no screening answered it correctly. Although the 
majority of patients with HBV or HCV who develop HCC have cirrhosis, HBV and HCV are 
able to cause HCC in the absence of cirrhosis [49, 97]. This misconception may have 
affected screening practice because patients without cirrhosis may feel safe at the 
moment and believe they have another stage to go through before developing HCC. In 
addition, 44.9% of patients with routine screening and 63.4% with irregular screening did 
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not know the purpose of the liver AFP test before participation in this study. Many patients 
underwent AFP simply because they were asked to do so by their hepatologists, but there 
was a lack of explanation and education about receiving HCC screening.  
 “Not aware that screening for HCC exists” was the most common reason for not 
having undergone screening, which illustrates a serious deficiency in HCC screening 
knowledge. Such lack of knowledge among high-risk patients indicates that insufficient 
knowledge and awareness also likely exists in the general Chinese population, which 
results in inadequate preventive measures and enables HCC to be prevalent. Another 
important barrier was “No symptoms or discomfort”, which was cited as the second most 
common reason for refusing cervical cancer screening among women from a region in 
China with high cervical cancer incidence [88]. In traditional Chinese culture, visiting 
physicians is usually for the purpose of treating and managing illnesses rather than 
prevention, putting an emphasis on dealing with health crises over health promotion [98]. 
Studies that examined cervical, breast, and colon cancer screening practices among 
Chinese American women and Chinese immigrants discovered that physician 
recommendation was a major factor for screening adherence [99-101]. Likewise in our 
study, “Lack of recommendation from physicians” was cited as one of the key reasons for 
not participating in screening. Since physicians are often regarded as authoritative figures 
in Chinese culture [102], it is crucial for Chinese physicians and healthcare providers to 
take the lead and educate patients about the importance of HCC screening. Whereas U.S. 
studies on HCC surveillance observed financial reasons to be a substantial barrier for 
screening [94, 95], only 16.0% of patients with incomplete or no screening listed financial 
difficulty as a barrier in our study. This finding is also consistent with our result that neither 
annual household income nor insurance status had a significant impact on screening 
practice. The reason could be due to the cost of HCC screening, in which a combination 
of AFP and ultrasound is listed to be 90 RMB (approximately U.S. $13) at Shanghai Public 
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Health Clinical Center and 200 RMB (approximately U.S. $30) at Hubei Third People’s 
Hospital. These prices are reasonable considering household income, and screening cost 
becomes even lower with insurance coverage. Other barriers observed included “Do not 
know the benefits of screening”, “Since HCC is difficult to treat, why bother undergo 
screening”, “Afraid of detecting HCC”, “Lack of time”, “Difficult to access medical facilities”, 
“Do not believe that HCC screening is an effective prevention”, and “Not afraid of 
developing HCC”. As shown, the majority of the barriers are associated with a lack of 
understanding, knowledge and awareness about HCC screening; therefore, there is a 
need to bring out public attention and correct these misconceptions. Improving an 
individual’s knowledge regarding HCC will likely lead to a change in behavior. Healthcare 
professionals and community leaders should provide extensive education to inform high-
risk populations about the importance of HCC screening and that screening is beneficial 
because treatments for HCC can be offered with early detection. Moreover, it is crucial to 
educate high-risk patients about adopting healthy lifestyles and continuously reinforce the 
importance of HCC screening.  
In China, many HBV carriers are living under a great amount of stress and are 
frequently facing discrimination in life and work due to social stigma. Discrimination 
against HBV carriers is a major issue in China, and many healthcare services even report 
a positive test result to the patient’s school or employer [7]. In addition, it is still a common 
belief that HBV is transmittable through eating together and contacts, which underlies the 
prejudice against infected individuals [103]. Since social pressure generated from the 
society may have deterred high-risk patients from undertaking screening, there is a need 
to identity individuals with psychological issues and offer the appropriate counseling, 
which could involve providing education regarding HCC, alleviating emotional stress, 
managing crisis, recommending lifestyle modifications, and giving encouragements.  
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The main strengths of this study are that the response rate was high and the 
sample size was large enough to generate statistically meaningful findings; however, this 
study is subject to some limitations. Since electronic medical record systems were not 
available at the studied institutions, formal verification for data accuracy was not 
performed. Although we relied on self-report, quality controls and best efforts were 
delivered to assure data collected were reliable. Since our collaborating institutions are 
major tertiary hospitals in large urban cities, and because major gaps in economic 
development and health disparities exist between urban and rural regions in China [104], 
future studies can be carried out in rural and less economically developed regions. It would 
be reasonable to assume that screening adherence rate in many economically 
impoverished regions in China is lower than the rate observed in our study. Moreover, 
since patients who visit healthcare facilities tend to have better health awareness, it would 
be of interest to investigate HCC screening practice among high-risk patients from a 
community-based setting in China.  
Since China alone accounts for half of the liver cancer cases and deaths globally, 
understanding the reasons for the lack of HCC screening in high-risk populations could 
assist healthcare professionals to develop more effective intervention methods for early 
detection. As screening helps to detect HCC at an early stage, effective treatments may 
be offered to achieve better chances of survival. Unlike the screening approaches 
formulated for certain other cancers, which target the general population, strategies for 
improving HCC screening should be different. Our findings suggest that appropriate and 
effective educational programs should be established. Chinese healthcare practitioners 
and community health promotion leaders should pursue an active role to implement and 
utilize educational programs as an intervention to improve high-risk patients’ awareness, 
knowledge and perceptions about HCC screening. These educational programs should 
target patients with low socioeconomic status, patients who reside in rural areas, as well 
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as middle-aged and older patients. Also, professional counseling could be provided to 
assist patients with social or psychological issues regarding hepatitis or HCC. In addition, 
the approach of entering high-risk patients into disease management programs and 
providing automatic reminders could potentially improve screening adherence [105, 106]; 
this calls for the implementation and adaptation of electronic health record systems in 
China. Further studies conducted in multiple diverse areas in China are warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
 
Table 1. A Comparison of Screening Practice by Sociodemographic Characteristics, 
Clinical Characteristics and Knowledge Score (N = 352) 
*Statistical significance at P <0.05 
 Routine 
Screening 
(N=176) N (%) 
Irregular 
Screening Interval 
(N=82) N (%) 
Incomplete/No 
Screening 
(N=94) N (%) 
P  
Value 
Age group (year)    0.57 
35-44 33 (18.8) 22 (26.8) 18 (19.2)  
45-54 65 (36.9) 24 (29.3) 33 (35.1)  
55-65 78 (44.3) 36 (43.9) 43 (45.7)  
Gender    0.12 
Male 117 (66.5) 70 (74.5) 64 (78.1)  
Female 59 (33.5) 24 (25.5) 18 (22.0)  
Residence    0.003* 
Urban 160 (90.9) 71 (86.6) 71 (75.5)  
Rural 16 (9.1) 11 (13.4) 23 (24.5)  
Household 
registration 
   0.003* 
Urban 145 (82.4) 67 (81.7) 61 (64.9)  
Rural 31 (17.6) 15 (18.3) 33 (35.1)  
Education level    <0.001* 
Middle school or below 45 (25.6) 25 (30.5) 55 (58.5)  
High school 71 (40.3) 39 (47.6) 28 (29.8)  
College or above 60 (34.1) 18 (22.0) 11 (11.7)  
Household income     <0.001* 
<40K 37 (21.0) 22 (26.8) 43 (45.7)  
40K-80K 66 (37.5) 33 (40.2) 33 (35.1)  
80K-150K 41 (23.3) 18 (22.0) 13 (13.8)  
>150K 32 (18.2) 8 (11.0) 5 (5.3)  
Insurance type    0.17 
UEBMI 129 (73.3) 56 (68.3) 54 (57.5)  
URBMI 16 (9.1) 10 (12.2) 13 (13.8)  
NCMS 12 (6.8) 7 (8.5) 16 (17.0)  
Out-of-pocket 12 (6.8) 6 (7.3) 5 (5.3)  
Other 7 (4.0) 3 (3.7) 6 (6.4)  
Family history    0.027* 
Yes 45 (25.6) 19 (23.2) 11 (11.7)  
No 131 (74.4) 63 (76.8) 83 (88.3)  
Hepatitis duration 
(year) 
   0.050 
0-9 47 (26.7) 24 (29.3) 40 (42.6)  
10-19 45 (25.6) 26 (31.7) 23 (24.5)  
≥20 84 (47.7) 32 (39.0) 31 (33.0)  
Cirrhosis status    0.017* 
Yes 78 (44.3) 27 (32.9) 26 (27.7)  
No 98 (55.7) 55 (67.1) 68 (72.3)  
Comorbidity    0.78 
0 88 (50.0) 37 (45.1) 52 (55.3)  
1 53 (30.1) 29 (35.4) 23 (24.5)  
2 23 (13.1) 10 (12.2) 14 (14.9)  
≥3 12 (6.8) 6 (7.3) 5 (5.3)  
Knowledge score, 
mean (SD) 
10.1 (2.5) 8.6 (2.6) 7.4 (2.5) <0.001* 
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Table 2. Multinomial Logistic Regression of the Effect of Sociodemographic 
Characteristics, Clinical Characteristics and Knowledge Score on Screening Practice (N 
= 352) 
 
*Statistical significance at P <0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Routine Screening vs.  
Incomplete/No Screening 
Irregular Screening Interval vs.   
Incomplete/No Screening 
 OR (95% CI) P Value OR (95% CI) P Value 
Gender     
Male Reference  Reference  
Female 1.56 (0.81, 3.00) 0.18 0.85 (0.41, 1.78) 0.66 
Education level     
Middle school or below Reference  Reference  
High school 2.80 (1.45, 5.41) 0.002* 2.72 (1.36, 5.46) 0.005* 
College or above 3.94 (1.67, 9.27) 0.002* 2.62 (1.02, 6.73) 0.045* 
Family history     
No Reference  Reference  
Yes 2.86 (1.28, 6.40) 0.011* 2.51 (1.08, 5.82) 0.033* 
Cirrhosis status     
No Reference  Reference  
Yes 2.39 (1.28, 4.46) 0.007* 1.40 (0.71, 2.76) 0.33 
Knowledge score  1.47 (1.30, 1.67) <0.001* 1.18 (1.04, 1.35) 0.013* 
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Table 3. A Comparison of Knowledge Score by Sociodemographic and Clinical 
Characteristics (N = 352) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Statistical significance at P <0.05 
 
 Knowledge Score 
 Mean SD P Value 
Age group (year)   0.003* 
35-44 9.9 3.0  
45-54 9.0 2.8  
55-65 8.6 2.7  
Gender   0.73 
Male 9.0 2.9  
Female 9.1 2.6  
Residence   <0.001* 
Urban 9.4 2.7  
Rural 7.1 2.6  
Household registration   <0.001* 
Urban 9.4 2.7  
Rural 7.7 2.6  
Education level   <0.001* 
Middle school or below 8.0 2.6  
High school 8.9 2.6  
College or above 10.7 2.5  
Household income (RMB)   <0.001* 
<40K 7.8 2.5  
40K-80K 9.0 2.7  
80K-150K 9.7 2.8  
>150K 10.7 2.6  
Insurance type   <0.001* 
UEBMI 9.4 2.7  
URBMI 8.8 2.4  
NCMS 6.8 2.5  
Out-of-pocket 9.6 3.0  
Other 8.8 3.1  
Family history   0.48 
Yes 9.2 3.0  
No 9.0 2.7  
Hepatitis duration (year)   <0.001* 
0-9 8.1 2.6  
10-19 9.2 2.6  
≥20 9.6 2.9  
Cirrhosis status   0.58 
Yes 9.1 3.0  
No 9.0 2.7  
Comorbidity   0.68 
0 9.1 2.9  
1 9.2 2.8  
2 8.6 2.6  
≥3 9.0 2.8  
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Table 4. Multiple Linear Regression of the Effect of Sociodemographic and Clinical 
Characteristics on Knowledge Score (N = 352) 
 Knowledge Score 
 β-
Coefficient 
SE 95% CI P Value 
Age group (year)     
35-44 Reference    
45-54 -0.98 0.38 (-1.73, -0.24) 0.010* 
55-65 -1.49 0.38 (-2.24, -0.75) <0.001* 
Gender     
Male Reference    
Female 0.72 0.30 (0.11, 1.31) 0.020* 
Residence     
Urban Reference    
Rural -1.25 0.41 (-2.06, -0.45) 0.002* 
Education level     
Middle school or below Reference    
High school 0.46 0.33 (-0.18, 1.10) 0.16 
College or above 1.67 0.41 (0.87, 2.47) <0.001* 
Household income (RMB)     
<40K Reference    
40K-80K 0.70 0.34 (0.03, 1.37) 0.041* 
80K-150K 0.65 0.44 (-0.22, 1.51) 0.14 
>150K 1.48 0.51 (0.48, 2.47) 0.004* 
Hepatitis duration (year)     
0-9 Reference    
10-19 0.92 0.34 (0.25, 1.59) 0.007* 
≥20 1.59 0.31 (0.98, 2.21) <0.001* 
*Statistical significance at P <0.05 
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Table 5. Barriers towards Participation in HCC Screening among Patients Who had 
Incomplete or No Screening (N = 94) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Barriers Frequency  
1. Not aware that screening for HCC exists 39 (41.5%) 
2. No symptoms or discomfort 36 (38.3%) 
3. Lack of recommendation from physicians 30 (31.9%) 
4. Do not know the benefits of screening 21 (22.3%) 
5. Since HCC is difficult to treat, why bother undergo screening   17 (18.1%) 
6. Financially difficult to afford screening 15 (16.0%) 
7. Afraid of detecting HCC 13 (13.8%) 
8. Lack of time 12 (12.8%) 
9. Difficult to access medical facilities   7 (7.4%) 
10. Do not believe that HCC screening is an effective prevention 5 (5.3%) 
11. Not afraid of developing HCC 3 (3.2%) 
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CHAPTER III 
ADHERENCE AND PERCEIVED BARRIERS TO ORAL ANTIVIRAL THERAPY FOR 
CHRONIC HEPATITIS B 
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Abstract 
Background: Globally, of the 248 million people chronically infected with the 
hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs) 
have been approved for the treatment of chronic HBV in China.  
Objectives: The aims of this study were to determine rates of adherence to NUC 
therapy in patients with chronic HBV, to identify the self-perceived barriers to adherence, 
and to examine the factors associated with adherence.  
Methods: Questionnaire-based interviews were administered among Chinese 
patients with chronic HBV at hepatology clinics of a tertiary hospital in the city of Wuhan, 
China. Adults aged 18 years or older prescribed with NUCs were recruited and interviewed 
to complete a 27-item questionnaire in a private setting, and adherence was measured 
using the Morisky Medication Adherence Scale (MMAS-8).  
Results: Among 369 participants, only 16.5% had high adherence (score of 8), 
32.2% had medium adherence (score of 6 to <8), and 51.2% were measured with low 
adherence (score of <6). A logistic regression model was used to determine the factors 
associated with medication adherence. Significant predictors of high adherence consisted 
of urban residency, non-cirrhotic status, not using prescribed pills other than HBV 
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medications, and reminders from family members. The five most common reasons for 
skipping NUCs were that medication(s) are expensive (48.7%), forgetfulness (45.1%), 
have experienced or worry about potential side effects (19.8%), do not want others to 
know about my medication(s) usage (18.5%), and ran out of pills and do not have time to 
refill (15.9%).  
Conclusions: This study revealed that adherence rates to oral antiviral therapy 
were far from optimal. Healthcare providers should actively inform and educate patients 
about the importance of adherence and the consequences for skipping NUCs. 
Additionality, the government should enter into negotiations with the generic drug 
manufacturers of entecavir to obtain less costly drug. 
 
Introduction 
 HBV infection is endemic in China. Globally, China is among the countries with a 
high prevalence of HBV infection. The biggest health concerns of HBV infection are risks 
associated with chronic hepatitis, including cirrhosis, liver failure and HCC [107]. It is 
estimated that 85% of HCC cases in China are HBV-related [31], and China accounts for 
half of the total number of liver cancer cases and deaths worldwide [4]. Currently, five oral 
nucleot(s)ide analogs (NUCs), conventional interferon alpha (IFN-α), and two formulations 
of pegylated interferon alpha (PEG-IFNα) have been approved for treating chronic HBV 
infection in China [54].  
Adherence to antiviral therapy is fundamental for the clinical management of 
patients with chronic HBV [108, 109]. Long-term viral suppression was found to be 
associated with histologic improvement in the reduction of fibrosis and ultimately 
regression of cirrhosis [110]. Furthermore, a study has demonstrated that adult patients 
with chronic HBV need over two years of NUC treatment to reduce risk of cirrhosis, HCC 
or HBV-related death [111]. In order to achieve and maintain virologic suppression, avoid 
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virologic breakthrough, and attain undetectable levels of HBV DNA, optimal medication 
adherence is essential [112]. Antiviral therapy functions to prevent, delay, and reverse 
disease progression, leading to improved disease management and ultimately result in 
better survival [113]. 
A limited number of studies have utilized questionnaires to investigate the 
adherence to HBV antiviral therapy and factors associated with adherence [58-60]; 
however, these studies were limited to small sample sizes. Additionally, there is a lack of 
research focused to assess the self-perceived barriers and facilitators for adherence to 
HBV antiviral therapy. Since China has a high prevalence of HBV infection, it is crucial to 
understand the adherence and obstacles for HBV treatment using a validated instrument. 
Findings generated from this study could potentially be utilized in developing strategic 
preventive measures to improve medication adherence in regions of the world with a high 
prevalence of HBV infection. The aims of this study were to i) determine rates of 
adherence to NUC antiviral therapy using the Morisky Medication Adherence Scale in 
Chinese patients with chronic HBV, ii) identify the self-perceived barriers to NUC 
adherence, and iii) investigate the impact of sociodemographic and clinical factors, as well 
as treatment-related factors and perceptions of disease on NUC adherence.  
 
Methods 
Study design and data collection 
This cross-sectional study was conducted from February to May 2017 at the 
Department of Hepatology of Hubei Third People’s Hospital, Wuhan, China. The Hubei 
Third People’s Hospital is a large tertiary hospital with areas in medicine, research, 
teaching, prevention and rehabilitation. It serves as the national base of standardized 
residency training and the national base of clinical trials for drug development. The study 
utilized a structured questionnaire, which was designed based on the opinions’ from 
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experts in hepatology and previous studies on HBV medication adherence [58, 59]. The 
source population comprised of chronic HBV patients who were prescribed with one or 
more NUCs, and eligible participants consisted of adults aged 18 years or older. Patients 
co-infected with HCV), hepatitis D or human immunodeficiency virus, pregnant patients, 
and patients prescribed with NUCs less than three months ago were excluded. A pilot test 
of 30 patients was conducted to determine the feasibility and suitability of the 
questionnaire, and adjustments of the questionnaire were made accordingly. An interview-
based, rather than a self-administered questionnaire was conducted to reduce the 
likelihood of participants skipping questions. Informed consent was obtained from all 
participants and in-person interviews were conducted in a private setting by a hepatologist 
in the hepatology clinics.  
 
Measures and assessment  
The questionnaire comprised of four sections. Section I consisted of 9 multiple-
choice and fill-in-the-blank questions concerning basic sociodemographic and clinical 
information. The factors of interest included age, gender, current region of residence, 
education level, annual household income, medical insurance status, duration of known 
HBV infection, liver cirrhosis status, and the presence of other chronic diseases. In China, 
three main types of social medical insurance programs have been established: Urban 
Employee’s Basic Medical Insurance (UEBMI) works to cover insurance for the urban 
working population, Urban Resident Basic Medical Insurance (URBMI) provides care for 
the unemployed urban residents, and New Rural Cooperative Medical System (NCMS) 
provides financial subsidies for residents from rural regions [114]. 
Medication adherence was assessed by the 8-item Morisky Medication Adherence 
Scale (MMAS-8) in Section II of the questionnaire [115]. The MMAS-8 is a simple, reliable, 
and widely used instrument for determining adherence to prescribed medications [116]. 
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The MMAS-8 has been demonstrated to be useful in identifying low adherence in clinical 
settings [117]. Moreover, a previous study has utilized the MMAS-8 to examine adherence 
to HBV treatment [118]. The Morisky Scale is comprised of 8 questions (score range: 0 to 
8), with each item measuring a specific medication adherence behavior. The first seven 
items are Yes-or-No questions and the last item has five options. Adherence levels of high, 
medium, and low are defined with MMAS-8 scores of 8 points, 6 to <8 points, and <6 
points, respectively. The validated Chinese translation was provided by Prof. Donald E. 
Morisky, as well as permission to use this scale. In Section III of the questionnaire, patients 
with moderate or low adherence were asked to choose the barrier(s) for taking NUCs or 
reason(s) for skipping NUCs.  
The last section comprised of 10 questions concerning treatment regimen and 
patient perceptions. Treatment-related questions consisted of type of NUC taken, duration 
of current antiviral therapy, use of other medications for treating HBV, number of other 
prescribed pills taken daily (exclude all medications used for HBV treatment), follow up 
regularly at the clinic, understanding the physicians’ recommendations, use of memory 
aids (e.g. clock alarm, phone alarm), and reminders from family members. In addition, 
participants were interviewed about their perceptions of disease condition and current 
health condition in general. The entire questionnaire can be found in Appendix C. 
 
Statistical analysis  
Data collected were coded and analyzed using SAS 9.4 (SAS Institute Inc., Cary, 
NC). A value of P < .05 in a two-tailed test was considered statistically significant. 
Descriptive statistics were performed, and variables were expressed as frequencies and 
percentages. The association of sociodemographic and clinical factors, as well as 
treatment-related factors and perceptions of disease with medication adherence levels 
were examined using χ2 test or Fisher Exact test. A multinominal logistic regression model 
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with stepwise model selection (inclusion with P < .10) was built to determine the 
independent predictors for medication adherence, and all factors from univariate analysis 
were inserted into the model. The adjusted odds ratio (OR) and 95% confidence intervals 
(CI) were generated in the final model. 
 
Results 
Patient characteristics 
A total of 369 valid questionnaires were collected, with a response rate of 92.5%. 
The mean age of the participants was 49.1 ± 13.3 years, and the average duration of 
known HBV infection and current antiviral therapy were 12.7 ± 9.4 years and 64.5 ± 55.4 
months, respectively. The majority of patients were males (65.3%), resided in urban 
regions (80.8%), graduated with a highest degree from high school (52.9%), had annual 
household income of 80K RMB (USD ~$12.3K) or lower (77.0%), had the UEBMI medical 
insurance (68.6%), were non-cirrhotic (68.0%), and did not present other chronic diseases 
(60.7%) (Table 6). A variety of treatment regimens were prescribed, with 337 patients on 
NUC monotherapy and 32 patients on NUC combination therapy. The majority of patients 
received entecavir (n = 224, 60.7%), followed by adefovir (n = 100, 27.1%), lamivudine (n 
= 45, 12.2%), telbivudine (n = 31, 8.4%) and tenofovir (n = 1, 0.3%). In addition, 28 patients 
(7.6%) received entecavir plus adefovir, and 4 patients (1.1%) received lamivudine plus 
adefovir.  
  
Medication adherence rates 
Adherence rates were determined using the Morisky Medication Adherence Scale. 
Based on the MMAS-8 scoring system, a total of 61 patients (16.5%) had high adherence, 
119 patients (32.2%) exhibited medium adherence, and 189 patients (51.2%) were 
measured with low adherence. A further analysis of the MMAS-8 data showed that overall, 
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41.2% of patients stated that they sometimes forget to take medication(s), and 34.7% 
reported of having missed taking medication(s) sometime within the past two weeks. A 
number of patients (15.2%) reported to have cut back or stopped taking medication(s) 
without telling their doctors because they felt worse, or because they felt the symptoms 
were under control (19.8%). Moreover, 89 patients (24.1%) reported of sometimes 
forgetting to bring along medication(s) when traveling or leaving home. The vast majority 
of patients (94.6%) took their medication(s) yesterday, but most patients (52.3%) felt that 
it is a hassle to stick with their current treatment plan. When asked about ‘how often do 
you have difficulty remembering to take all your antiviral medication(s)?’, 30.9% 
responded never/rarely, 27.1% once a while, 31.2% sometimes, 7.9% usually, and 3.0% 
all the time.  
 
Factors associated with medication adherence 
The association of patient sociodemographic and clinical factors with medication 
adherence was generated from univariate analysis. As shown in Table 6, adherence was 
significantly associated with region of residence (P < .001), education level (P < .001), 
annual household income (P = .003), type of medical insurance (P < .001) and cirrhosis 
status (P < .001). Patients with education level of college or above, annual household 
income of greater than 150K RMB (USD ~$23K), the UEBMI medical insurance, as well 
as patients without cirrhosis and resided in urban regions were more likely to have high 
adherence. Table 7 presents the association of treatment-related factors and perceptions 
of disease with medication adherence. Adherence was significantly associated with 
duration of current antiviral therapy (P =.02), number of other prescribed pills taken daily 
(P =.016), follow up regularly at the clinic (P =.016), reminders from family members (P 
=.049), and perception of current health condition (P =.021). As shown, patients with a 
shorter duration of current treatment at 0–24 months, not using other prescribed pills, 
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followed up regularly at the clinic, received reminders from family members, and perceived 
their current health condition to be very good were more likely to have high adherence.     
 
Predictors of medication adherence 
Table 8 illustrates the results from logistic regression analysis on the determinants 
of medication adherence. Region of residence, cirrhosis status, number of other 
prescribed pills taken daily, and reminders from family members were significant 
predictors of adherence to NUCs. Patients residing in urban regions were 4.88 (95% CI: 
1.75–13.51; P =.002) times more likely of having high adherence as opposed to low 
adherence when compared to patients from rural regions. Likewise, patients without 
cirrhosis were 3.17 (95% CI: 1.26–7.95; P =.014) times more likely to have high adherence 
compared to cirrhotic patients. Additionally, patients receiving reminders from family 
members were 3.13 (95% CI: 1.53–6.41; P =.002) times more likely to belong to the high 
adherence group. Compared to patients taking 2 or more other prescribed pills daily, those 
not using other prescribed pills were more likely to exhibit high adherence versus medium 
(OR: 0.22; 95% CI: 0.05–0.92; P =.038) or low adherence (OR: 0.18; 95% CI: 0.05–0.73; 
P =.017).  
 
Perceived barriers toward medication adherence 
The frequencies of self-perceived barriers were analyzed and are described in 
Table 9. The top five reasons for skipping NUCs were that ‘Medication(s) are expensive 
and difficult to afford’ (48.7%), ‘Forgetfulness’ (45.1%), ‘Have experienced or worry about 
potential side effects’ (19.8%), ‘Do not want others to know about my medication(s) usage’ 
(18.5%), and ‘Ran out of pills and do not have time to refill’ (15.9%). 
 
Discussion 
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To our knowledge, this is the largest study utilizing self-report questionnaires to 
access the adherence and self-perceived barriers to HBV oral antiviral therapy. Based on 
our findings, adherence to NUCs among patients with chronic HBV was found to be very 
poor, with 51.2% of patients reported to have low adherence. In comparison, a similar 
study that utilized structured questionnaires and conducted in Australia found that 74.1% 
of patients reported an adherence rate of 100% [59], while 66% and 52% of patients in 
similar studies conducted in the United States and the Netherlands were measured with 
an adherence rate of 90% [58, 60]. In contrast, only 16.5% of patients from this study 
scored an adherence of 100%. Chotiyaputta et al. [58] observed that 73% of patients 
reported they did not miss a single dose of medication during the past 30 days, whereas 
we found that just 65.3% of patients did not miss taking medication(s) during the past 2 
weeks. Furthermore, rates of high adherence reported in secondary studies that used 
pharmacy and medical records were also significantly higher than rate observed in our 
study [108, 119-121].  
 It is widely known that major gaps in the economic development and health 
disparities exist between urban and rural regions in China [122]. Our findings 
demonstrated that urban residents were significantly more likely to have high adherence 
compared to residents from rural regions. In China, rural patients with chronic HBV often 
have issues in accessing quality health services due to the lack of specialized clinical 
services established in rural areas [123]. The majority of quality hospitals are located in 
the urban regions with better trained healthcare professionals and more advanced 
technology [124]. Furthermore, HBV has been considered as an economically 
catastrophic disease, and costs of treatment are a major burden for rural patients [123]. 
An estimated figure has shown that less than 5% of rural patients are able to afford one 
year of treatment as opposed to 40% of patients in more developed regions [123]. In 
addition to issues concerning accessibility and costs of treatment, Chinese patients in rural 
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regions also have poor health awareness; many infected-individuals are unaware of their 
HBV infection until symptoms appear [125].   
The finding that cirrhotic patients were less adherent to NUCs may be explained 
by that patients who had better treatment adherence were less likely to develop cirrhosis. 
Furthermore, our results illustrated that patients taking 2 or more other prescribed pills on 
a daily basis were cited to be more likely of having low adherence. Four studies that 
investigated medication nonadherence among elderly populations prescribed with various 
medications have shown that a greater number of drugs was associated with worse 
adherence [126]. In a large-scale study, researchers examined the effect of previous 
prescription burden on adherence rates when antihypertensive or lipid-lowering therapy 
was added, and found that rates dropped to 41%, 30% and 20% among patients who 
received 0, 2, and 10 or more previous medications, respectively [127]. Polypharmacy is 
associated with nonadherence due to a number of factors, including regimen complexity, 
time and commitment, treatment costs, financial reimbursement, difficulty in managing co-
existing illnesses, side effects, multiple prescribers, access to care, etc. [128]. 
Consistent with our findings, numerous studies have found a positive relationship 
between family support interventions and medication adherence [129]. A lack of family 
and social support has shown to be a predictive factor of nonadherence among patients 
treated for chronic illnesses [128], and research on the adherence to type II diabetes 
treatment demonstrated that family support was the strongest predictor of adherence [130]. 
Results generated from univariate analysis indicated that higher annual household income 
was significantly associated with better adherence, and Chotiyaputta et al. [58] also 
observed similar result. In contrast, while studies have observed that patients with poor 
adherence were more likely to be younger [58, 60, 121], an association between age and 
adherence was not found in this study, which may be explained by racial and ethnic 
differences in the study populations.   
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 ‘Medication(s) are expensive and difficult to afford’ was the most common reason 
for skipping NUCs. Over 60% of patients in this study were prescribed with entecavir, 
which is known for its higher cost and unaffordability to many Chinese patients. However, 
research has shown that entecavir is still more cost-effective than other NUCs [131]. One 
study evaluated the cost-effectiveness of NUCs in China, and assessed the thresholds at 
which the drugs would be cost-saving to the national treatment program [38]. The 
investigators found that generic entecavir would be the most cost-effective therapy unless 
the cost of tenofovir drops. Currently, several pharmaceutical companies in China are 
producing generic versions of entecavir, and the lowest reported price is at $1,258 (~8,556 
RMB) per person-year or $105 (~714 RMB) per person-month [132]. Additionally, one 
study that estimated the cost of manufacturing generic entecavir at a minimum target price 
found that generic entecavir could actually be produced at $36 (~245 RMB) per person-
year or $3 (~20 RMB) per person-month, which is substantially lower than the current price 
[133]. Since the patent for entecavir has expired, it would be cost-effective for the 
government to enter into negotiations with generic drug manufacturers of entecavir to 
obtain a less costly drug. Within a competitive market, an affordable and large-scale 
treatment system could provide immense health benefits to patients with chronic HBV.  
 Another common barrier of medication adherence was ‘Forgetfulness’, which was 
cited as the main reason for skipping NUCs in the study conducted in Australia [134]. 
Forgetfulness can be partly dealt through providing reminders, such as from families and 
close friends, and the use of alarm clocks or automated text messages [134]. Nonetheless, 
forgetfulness can be influenced by cognitive factors [59], including a lack of awareness 
and knowledge concerning the health risks associated with disease condition. Therefore, 
healthcare providers should actively inform and educate patients about the importance of 
adhering to antiviral therapy and the potential consequences for skipping NUCs. One 
study based on a review of medical records of 69 immigrant patients in Chicago 
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discovered that concerns about the long-term safety of NUCs was cited as one of the main 
barriers to treatment initiation and one of the main reasons for treatment discontinuation 
[120]. Likewise in our study, ‘Have experienced or worry about potential side effects’ was 
identified as the third most common barrier to NUC adherence. This illustrates a 
misconception about NUCs; even though treatment of chronic HBV can often be life-long, 
NUCs are generally safe and well-tolerated by patients [135]. Furthermore, a large number 
of patients cited ‘Do not want others to know about my medication(s) usage’ as a perceived 
barrier. In China, patients with chronic HBV are living under a great amount of emotional 
distress and often face discrimination in life and work. Although HBV check-ups for 
employment and school enrollment have been banned since 2010, some employers still 
request job applicants to disclose HBV test results [136]. As a result, fear of disclosing 
HBV status may have negatively affected adherence to treatment. Therefore, with the help 
of psychiatrists and clinical psychologists, it would be beneficial to identify patients with 
psychological and emotional issues and offer the appropriate counseling, which would 
consist of alleviating emotional stress, overcoming fear, managing crises, and giving 
encouragements. Furthermore, ‘Ran out of pills and do not have time to refill’, ‘Feel better 
already and do not think it is necessary to continue’ and ‘Multiple medications are taken 
daily, difficult to track dose’ were other barriers that had an impact on NUC adherence. 
Nevertheless, these barriers were not cited as common reasons for skipping NUCs 
reported by Giang et al. [59].  
This study is subject to certain limitations that should be addressed. As a cross-
sectional study, significant association between the factors of interest and outcome can 
be difficult to interpret, and causality cannot be established as correlation does not imply 
causation. For instance, non-cirrhotic status was a significant predictor of high adherence, 
but it is difficult to determine whether this was because better NUC adherence served to 
prevent adherent patients from developing cirrhosis, or that patients without cirrhosis tend 
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to have better adherence. Furthermore, a meta-analysis consisting of studies on NUC 
adherence indicated that studies rely on patient self-report may to subject to 
overestimation when compared to secondary studies using data from pill count and 
pharmacy refill claims [108]. The potential inflation in reporting may be a result of reporting 
bias. Lastly, since China is a culturally and economically diverse nation, findings 
generated from this study are subject to geographical limitations and should be taken into 
account when making application of the results in different parts of the world as well as in 
different regions of China.  
The finding of poor medication adherence among Chinese patients taking NUCs 
should generate public attention, and calls for healthcare providers to work collaboratively 
with researchers and community health leaders to develop more effective interventional 
methods to improve NUC adherence. These interventional programs should target 
patients from rural regions, patients with low socioeconomic status, cirrhotic patients, and 
patients prescribed with multiple medications. Additionally, patients with severe emotional 
distress or at risk for mental disorders should be identified and be provided with 
professional counseling to cope with social and psychological issues. Further studies 
should focus to investigate the efficacy and impact of medication adherence on viral 
suppression, and the rate of adherence needed to prevent antiviral resistance in Chinese 
patients with chronic HBV. 
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Table 6. A comparison of adherence to HBV antiviral therapy by patient sociodemographic 
and clinical characteristics (n = 369). 
 
 
Characteristics 
High 
Adherence  
(n=61) n (%) 
Medium 
Adherence  
(n=119) n (%) 
Low  
Adherence  
(n=189) n (%)  
Total 
Count 
(n=369) 
P 
Value 
 
Age group (years) 
     
.07 
18–39 14 (15.2) 34 (37.0) 44 (47.8) 92  
40–49 21 (20.6) 39 (38.2) 42 (41.2) 102  
50–59 11 (13.6) 26 (32.1) 44 (54.3) 81  
≥60 15 (16.0) 20 (21.3) 59 (62.8) 94  
Gender     .51 
Male 36 (14.9) 78 (32.4) 127 (52.7) 241  
Female 25 (19.5) 41 (32.0) 62 (48.4) 128  
Region of residence     <.001 
Urban 55 (18.5) 110 (36.9) 133 (44.6) 298  
Rural 6 (8.5) 9 (12.7) 56 (78.9) 71  
Education level     <.001 
Middle school or below 9 (11.4) 18 (22.8) 52 (65.8) 79  
High School 32 (16.4) 49 (25.1) 114 (58.5) 195  
College or above 20 (21.1) 52 (54.7) 23 (24.2) 95  
Household income (RMB)    .003 
<50K 15 (15.0) 21 (21.0) 64 (64.0) 100  
50K–80K 29 (15.8) 59 (32.1) 96 (52.2) 184  
80K–150K 13 (19.7) 28 (42.4) 25 (37.9) 66  
>150K 4 (21.1) 11 (57.9) 4 (21.1) 19  
Type of insurance¶     <.001 
UEBMI 51 (20.2) 89 (35.2) 113 (44.7) 253  
URBMI 3 (13.0) 8 (34.8) 12 (52.2) 23  
NCMS 3 (4.7) 8 (12.5) 53 (82.8) 64  
OOP 2 (18.2) 3 (27.3) 6 (54.6) 11  
Others 2 (11.1) 11 (61.1) 5 (27.8) 18  
Duration of HBV infection (years)    .06 
0–5 20 (18.9) 36 (34.0) 50 (47.2) 106  
6–15 22 (15.2) 56 (38.6) 67 (46.2) 145  
>15 19 (16.1) 27 (22.9) 72 (61.0) 118  
Cirrhosis status     <.001 
Yes 9 (7.6) 25 (21.2) 84 (71.2) 118  
No 52 (20.7) 94 (37.5) 105 (41.8) 251  
Other chronic diseases    0.12 
0 39 (17.4) 82 (36.6) 103 (46.0) 224  
1 13 (13.5) 24 (25.0) 59 (61.5) 96  
≥2 9 (18.4) 13 (26.5) 27 (55.1) 49  
¶Abbreviation: UEBMI, Urban Employee’s Basic Medical Insurance; URBMI, Urban Resident 
Basic Medical Insurance,      NCMS, New Rural Cooperative Medical System; OOP, out-of-
pocket.  
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Table 7. A comparison of adherence to HBV antiviral therapy by treatment-related 
characteristics and perceptions of disease (n = 369).  
 
 
Characteristics 
High 
Adherence  
(n=61) n (%) 
Medium 
Adherence  
(n=119) n (%) 
Low  
Adherence  
(n=189) n (%)  
Total 
Count 
(n=369) 
P 
Value 
 
Duration of current therapy (months) 
    
.003 
0–24 21 (27.6) 26 (34.2) 29 (38.2) 76  
25–60 23 (13.3) 64 (37.0) 86 (49.7) 173  
>60 17 (14.2) 29 (24.2) 74 (61.7) 120  
Use of other medications to treat HBV    .64 
Yes, Chinese medicine 20 (14.4) 41 (29.5) 78 (56.1) 139  
Yes, Western medicine 2 (13.3) 6 (40.0) 7 (46.7) 15  
No 39 (18.1) 72 (33.5) 104 (48.4) 215  
Number of prescribed pills taken daily¶    .002 
0 49 (19.8) 89 (36.0) 109 (44.1) 247  
1 8 (13.1) 14 (23.0) 39 (63.9) 61  
≥2 4 (6.6) 16 (26.2) 41 (67.2) 61  
Regularly visit clinic for HBV   .016 
Yes 55 (17.5) 108 (34.4) 151 (48.1) 314  
No 6 (10.9) 11 (20.0) 38 (69.1) 55  
Understand what the physicians  
recommend 
   .62 
Yes 56 (17.1) 106 (32.4) 165 (50.5) 327  
No 5 (11.9) 13 (31.0) 24 (57.1) 42  
Use of memory aids    .28 
Yes 4 (10.8) 16 (43.2) 17 (46.0) 37  
No 57 (17.2) 103 (31.0) 172 (51.8) 332  
Reminders from family members    .049 
Yes 28 (21.7) 45 (34.9) 56 (43.4) 129  
No 33 (13.8) 74 (30.8) 133 (55.4) 240  
Perception of disease conditionδ    .12 
Severe 6 (16.7) 9 (25.0) 21 (58.3) 36  
Moderate 24 (15.7) 41 (26.8) 88 (57.5) 153  
Mild 26 (16.5) 62 (39.2) 70 (44.3) 158  
Don’t know 5 (22.7) 7 (31.8) 10 (45.5) 22  
Perception of current health condition    .021 
Very good 5 (45.5) 3 (27.3) 3 (27.3) 11  
Good 20 (17.5) 43 (37.7) 51 (44.7) 114  
Fair 30 (14.6) 67 (32.5) 109 (52.9) 206  
Poor 6 (15.8) 6 (15.8) 26 (68.4) 38  
   ¶ HBV medications are not included. 
   δParticipants who answered ‘don’t know’ were excluded from analysis. 
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Table 8. Multinomial logistic regression of the effect of sociodemographic characteristics, 
clinical characteristics, treatment-related characteristics and perceptions of disease on 
adherence to HBV antiviral therapy (n = 369). 
 
 
Characteristics 
High Adherence  
versus  
Medium Adherence 
High Adherence  
versus 
Low Adherence 
  
OR (95% CI) 
 
P Value 
 
OR (95% CI) 
 
P Value 
Region of residence     
Rural Reference  Reference  
Urban 0.79 (0.24, 2.61) .70 4.88 (1.75, 13.51) .002 
Cirrhosis status     
Yes Reference  Reference  
No 1.33 (0.48, 3.65) .58 3.17  (1.26, 7.95) .014 
Number of prescribed pills taken daily¶    
0 Reference  Reference  
1 0.89 (0.30, 2.61) .83 0.45 (0.17, 1.20) .11 
≥2 0.22 (0.05, 0.92) .038 0.18 (0.05, 0.73) .017 
Reminders from family members    
No Reference  Reference  
Yes 1.44 (0.71, 2.93) .31 3.13 (1.53, 6.41) .002 
¶ HBV medications are not included. 
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Table 9. Perceived barriers toward compliance to HBV antiviral therapy among patients 
with medium and low adherence in rank order (n = 308). 
Barriers n (%) 
 
1. Medication(s) are expensive and difficult to afford 
 
150 (48.7) 
2. Forgetfulness 139 (45.1) 
3. Have experienced or worry about potential side effects 61 (19.8) 
4. Do not want others to know about my medication(s) usage 57 (18.5) 
5. Ran out of pills and do not have time to refill   49 (15.9) 
6. Feel better already and do not think it is necessary to continue   41 (13.3) 
7. Multiple medications are taken daily and cannot keep track of dose for 
each 
37 (12.0) 
8. Cannot tell the difference between taking/not taking medication(s) 33 (10.7) 
9. Insurance does not provide coverage when cost exceeds the limit 32 (10.4) 
10. Emotionally distressed about disease condition and have no desire to 
continue 
15 (4.9) 
11. Physician did not inform me about the importance of taking 
medication(s) timely 
7 (2.3) 
12. Difficulty swallowing 3 (1.0) 
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CHAPTER IV 
SURGICAL DELAY IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS 
WITH HEPATOCELLULAR CARCINOMA 
 
Publication Acknowledgment: 
Xu K, Watanabe-Galloway S, Rochling FA, Farazi PA, Monirul Islam KM, Wang H, Luo J. 
Surgical Delay is Associated with Improved Survival in Hepatocellular Carcinoma: Results 
of the National Cancer Database. Journal of Gastrointestinal Surgery. 2018. DOI: 
10.1007/s11605-018-3925-4.   
 
Abstract 
Background: Hepatocellular carcinoma (HCC) is one of the fastest growing 
causes of cancer-related death in the United States. Studies that investigated the impact 
of HCC therapeutic delays are limited to single centers, and no large-scale database 
research has been conducted. This study investigated the association of surgical delay 
and survival in HCC patients. 
Methods: Patients underwent local tumor destruction and hepatic resection for 
stage I-III HCC were identified from the 2004-2013 Commission on Cancer’s National 
Cancer Database. Surgical delay was defined as >60 days from the date of diagnosis to 
surgery. Generalized linear mixed model assessed the demographic and clinical factors 
associated with delay, and frailty Cox proportional hazards analysis examined the 
prognostic factors for overall survival.  
Results: 12,102 HCC patients met the eligibility criteria. Median wait time to 
surgery was 50 days (interquartile range: 29–86), and 4,987 patients (41.2%) had surgical 
delay. Delayed patients demonstrated better 5-year survival for local tumor destruction 
(29.1% vs. 27.6%; P=.001) and resection (44.1% vs. 41.0%; P=.007). Risk-adjusted model 
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indicated that delayed patients had a 7% decreased risk of death (HR: 0.93; 95% CI: 0.87–
0.99; P=.027). Similar findings were also observed using other wait time cutoffs at 50, 70, 
80, 90 and 100 days. 
Conclusions: A plausible explanation of this finding may be case prioritization, in 
which patients with more severe and advanced disease who were at higher risk of death 
received earlier surgery, while patients with less aggressive tumors were operated on later 
and received more comprehensive preoperative evaluation. 
 
Introduction 
In the United States, hepatocellular carcinoma (HCC) is one of the fastest growing 
causes of cancer-related death, and death rates have doubled since the mid-1980s [11]. 
According to 2017 estimates, there were 40,710 newly diagnosed cases and 28,920 
associated deaths of liver cancer in the U.S [22]. The detrimental effect of HCC is indicated 
by its poor survival, with an estimated 5-year relative survival rate of just 17.7% [12]. Early-
stage HCC patients can receive potentially curative options, such as liver transplantation, 
partial resection, and radiofrequency ablation (RFA) [36]. Due to the shortage of liver 
donors with potential recipients outnumbering donors, and a lack of access to 
transplantation centers [64], many surgeons perform resection and locoregional therapies 
as alternative treatments or as bridging therapy to prevent tumor progression [137].  
Due to the poor prognosis of HCC, it is necessary to initiate early active therapy 
once the disease is diagnosed. Furthermore, the natural course of untreated HCC is 
associated with advanced cancer staging [138]. The transition from diagnosis to treatment 
is complex and often requires multiple steps and many healthcare providers [139]. This 
transition involves decision-making on the optimal treatment, patient referral, appointment 
scheduling, preoperative clearance, and patient adherence in undertaking treatment [13]. 
These steps can occur in isolation or in combination, which often makes timely intervention 
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difficult to accomplish. An obstacle that occurs in any stage could result in treatment delay. 
A systematic review consisting of 177 studies investigated the association between time 
to diagnosis, treatment, and clinical outcomes across different cancer types [140]. 
Although there are conflicting findings on the impact of delay from diagnosis to treatment 
in various malignancies, a large number of cancer studies have reported that prolonged 
wait time to surgery was associated with less favorable outcomes [140]. 
Currently, there are no established guidelines for defining delay in HCC-directed 
surgery or the optimal time interval from diagnosis to surgery. Several studies have 
investigated the clinical impact of HCC therapeutic delays or prolonged wait time on 
outcomes in patients who underwent locoregional therapies [14-16], resection [17, 18], 
and with different treatments analyzed altogether [13, 19]. Nevertheless, the findings 
produced inconsistent results and most were restricted to single centers with limited 
sample sizes. As of this date, no large-scale database analysis has been conducted on 
this matter. To address the aforementioned gap, we conducted a retrospective study 
utilizing data drawn from the Commission on Cancer’s National Cancer Database (NCDB) 
2004–2013 Participant User Data File for liver cancer. The main objectives of this study 
were to identify the demographic and clinical factors associated with delay in HCC surgical 
treatment, and to evaluate the relationship between surgical delay and long-term survival 
in HCC patients.  
 
Methods 
Data source and study population 
The NCDB is a nationwide, facility-based, comprehensive clinical oncology dataset 
that consists of 70% of newly diagnosed malignancies in the United States [141]. The 
NCDB is a jointly sponsored program of the American College of Surgeons Commission 
on Cancer (CoC) and the American Cancer Society. It is sourced from hospital registry 
77 
 
 
 
data that are collected prospectively from more than 1,500 commission-accredited cancer 
programs in the U.S. and Puerto Rico, and contains more than 34 million historical records 
of adult patients 18 years old or older [141].  
Cases selected for analysis were comprised of cancers reported with International 
Classification of Diseases for Oncology, 3rd edition (ICD-O-3), topographical code C22.0 
(liver) and histopathologic types 8170–8175 (hepatocellular carcinoma) (n=118,800). The 
study solely consisted of cases with a malignant primary tumor site, and cases were 
staged in accordance with the 6th and 7th editions of the American Joint Committee on 
Cancer (AJCC) staging system. Based on the eligibility criteria (Figure 3 summarizes the 
patient selection process), we included HCC patients surgically treated with local tumor 
destruction (LTD) and hepatic resection. For disease stage, the analysis was limited to 
cases with stage I to III disease. Clinical stage was given priority and pathologic stage was 
used when clinical stage was not reported. Patients with a sequence number other than 
“00” or “01” were excluded. Sequence code “00” indicates that the patient had only one 
lifetime cancer diagnosis and “01” represents that the reported tumor was the first of 
multiple diagnoses. Since wait time to surgery was based on the number of days between 
date of diagnosis to date of the most definitive surgery, patients who received cancer-
directed surgery prior to undergoing definitive surgery were excluded. We further excluded 
patients whose wait time between diagnosis and definitive surgery was unavailable, as 
well as patients with definitive surgery performed past two years after diagnosis to 
eliminate for possible outliers. Cases were excluded if the diagnosis date was the same 
as date of definitive surgery, which indicated an emergent procedure or coding error. The 
final study population consisted of 12,102 patient-level observations. Survival data were 
available for patients diagnosed between 2004 and 2012 (n=10,285), and those 
diagnosed in 2013 were not included in survival analysis (n=1,817).  
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Data definitions and coding 
Wait time to surgery was classified as a dichotomous outcome of “non-delayed” 
and “delayed” groups. The date of diagnosis was coded as that of the most definitive 
method of diagnostic confirmation, and diagnosis was primarily based on histologic or 
cytologic confirmation of biopsy specimens (77.1%) and imaging techniques (20.1%). 
Based on the data distribution and proportionality, and a review of similar studies that 
defined delay in patients who underwent locoregional therapies or resection [14, 19, 142], 
delay in surgery was defined as an interval of longer than 60 days.  
For the variables used in this study, facility type was classified as comprehensive 
community cancer program, community cancer program, academic research cancer 
program, and integrated network cancer program. Patient demographic data included age 
at diagnosis, gender, race/ethnicity, insurance status, travel distance to treatment facility, 
and Charlson-Deyo comorbidity score, which is a comorbidity index based on ICD 
diagnosis codes. Clinical data consisted of AJCC TNM stage, preoperative serum alpha-
fetoprotein (AFP), size of primary tumor, tumor grade (collected at pathologic diagnosis), 
Model for End-Stage Liver Disease (MELD) score, and surgical intervention of primary site 
(LTD and resection). Treatment surgery was defined as cancer-directed surgical 
intervention, excluding incisional biopsy. In the database, LTD included but was not limited 
to RFA, electrocautery ablation, laser ablation, photodynamic therapy, cryosurgery, 
percutaneous ethanol injection, and acetic acid injection. Partial or simple removal of the 
primary tumor site, which consisted of wedge resection, segmental resection, lobectomy, 
and extended lobectomy were considered as surgical resection.  
  
Statistical analysis 
All data analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, NC). 
Descriptive statistics were performed on patient demographics and clinical characteristics. 
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Chi-square test was utilized to examine the association of categorical variables, and 
Mann-Whitney U nonparametric test reported mean and standard deviation for the 
continuous variable. To identify factors associated with surgical delay, all demographic 
and clinical factors with the exception of MELD score were first assessed in univariate 
analysis. The candidate variables with statistical significance (inclusion P <0.10) were then 
entered into a multivariate generalized linear mixed model accounting for clustering of 
outcomes within hospitals. Patient survival was determined in months from the date of 
diagnosis to the date of last contact or death as a result of any cause, and patients were 
censored at the time of lost to follow-up. The 5-year unadjusted survival based on time 
from diagnosis to surgery was examined using Kaplan-Meier plots stratified by surgical 
intervention, and significance was evaluated by log-rank test. A Cox proportional hazards 
frailty model adjusting for all factors (except for MELD score) was built to determine the 
predictors of overall survival and adjusted risk ratios. Since components of the MELD 
score were included in the database starting 2010, we were not able to adjust for this 
variable in survival analysis due to insufficient years of follow-up. In addition to using 60 
days as the main cutoff point to define surgical delay, survival was further evaluated using 
wait time cutoffs at 50, 70, 80, 90 and 100 days, adjusting for demographic and clinical 
factors. For all tests, a two-tailed P value of less than 0.05 was considered statistically 
significant.  
As the NCDB is a de-identified database, this study was exempted from review by 
the University of Nebraska Medical Center Institutional Review Board.  
 
Results 
Patient demographics 
The median follow-up time of the entire cohort was 25.9 months (range: 0–130.0 
months), and median wait time from diagnosis to definitive surgery was 50 days 
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(interquartile range: 29–86 days).  Figure 4 illustrates the distribution of wait time to 
surgery by month-intervals. A total of 4,987 patients (41.2%) had a wait time >60 days 
after date of HCC diagnosis. Within the delayed group, 85 patients (1.7%) underwent 
surgery after a year since diagnosis. Among all patients, 52.5% underwent LTD and 47.5% 
received resection. The mean age of diagnosis was 62.5 years and most patients were 
male (72.5%).  Based on patient demographic characteristics (Table 10), delayed patents 
were more likely be male (74.5% vs. 71.1%), African American race (16.2% vs. 13.1%), 
Medicaid holder (16.6% vs. 12.3%), and traveling for >100 miles to treatment facilities 
(12.3% vs. 10.6%). There was also a greater proportion of delayed patients treated in 
academic research cancer centers (71.5% vs. 66.5%). In terms of clinical characteristics, 
there was a greater proportion of non-delayed patients who had stage III disease (18.6% 
vs. 13.9%), with primary tumor >5 cm (36.3% vs. 25.5%), and having poorly 
differentiated/undifferentiated tumor (14.9% vs. 9.2%). Furthermore, in comparison, 
delayed patients tended to have underwent surgical resection (53.8% vs. 38.7%). 
 
Independent factors associated with surgical delay 
Table 11 outlines the results from multivariate analysis, and presents the 
demographic and clinical factors that were significantly associated with wait time to 
surgery. As shown, travel distance to treatment facility of >100 miles versus ≤10 miles 
increased odds of delay by 25% (OR: 1.25; 95% CI: 1.08–1.46). Female patients had a 
lower odds for experiencing delay (OR: 0.85; 95% CI: 0.78–0.94), and African Americans 
had a higher odds for having delayed surgery compared to non-Hispanic Caucasian 
patients (OR: 1.32; 95% CI: 1.17–1.49). Likewise, the odds for delay was higher among 
Medicaid beneficiaries compared to private insurance holders (OR: 1.28; 95% CI: 1.13–
1.45). Clinically, patients with poorly differentiated or undifferentiated tumor had a lower 
odds for delayed surgery compared to those with well differentiated tumor (OR: 0.70; 95% 
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CI: 0.60–0.83), and this was also the trend for larger tumor versus tumor <2 cm (2-5 cm 
vs. <2 cm [OR: 0.87; 95% CI: 0.77–0.99]; >5 cm vs. <2 cm [OR: 0.70; 95% CI: 0.60–0.81]). 
Moreover, Compared to LTD intervention, patients treated with resection were less likely 
to experience delay (OR: 0.70; 95% CI: 0.63–0.78).   
 
Estimates of survival probability  
In this cohort, the median survival was 37.7 months for delayed patients and 36.6 
months in patients without surgical delay. Figure 5 presents the Kaplan-Meier estimates 
of wait time to surgery, and Figure 6 details the unadjusted stage-specific survival 
probability. For all stages combined, compared to patients without delay, delayed patients 
had significantly better 5-year survival for LTD (29.1% vs. 27.6%; P =.001) and resection 
(44.1% vs. 41.0%; P <.001). Likewise, this trend was correspondingly observed for 3-year 
survival (delayed vs. non-delayed: LTD [45.1% vs. 42.8%]; resection [61.8% vs. 56.7%]), 
and 1-year survival (delayed vs. non-delayed: LTD [82.7% vs. 74.8%]; resection [85.4% 
vs. 80.1%]). For stage-specific 5-year survival, more favorable prognosis was observed in 
delayed patients who underwent LTD for stage II (28.7% vs. 23.6%; P =.008) and stage 
III disease (11.9% vs. 11.4%; P =.003), and surgical resection for stage III disease (27.2% 
vs. 22.0%; P =.002). In sum, no comparison revealed a significantly higher survival 
probability among patients without delay. 
 
Independent factors associated with risk-adjusted overall survival  
As indicated in Table 12, patients who received surgery >60 days after diagnosis 
date had a 7% decreased risk of death than patients with wait time ≤60 days (HR: 0.93; 
95% CI: 0.87–0.99; P =.027). Compared to cases treated in comprehensive community 
cancer programs, those who received care in academic research cancer programs had a 
14% decreased risk of mortality (HR: 0.86; 95% CI: 0.79–0.94). Of the demographic 
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factors, Asian race was a predictor of decreased mortality risk (HR: 0.76; 95% CI: 0.68–
0.84). Significant prognostic factors for worse survival consisted of Medicaid (HR: 1.12; 
95% CI: 1.00–1.24) and Medicare insurance coverage (HR: 1.12; 95% CI: 1.03–1.22), 
Charlson-Deyo score ≥2 (HR: 1.19; 95% CI: 1.09–1.29), stage II (HR: 1.11; 95% CI: 1.03–
1.20) and stage III disease (HR: 1.51; 95% CI: 1.37–1.67), elevated AFP level (>500 ng/ml) 
(HR: 1.23; 95% CI: 1.15–1.33), and primary tumor >5 cm (HR: 1.24; 95% CI: 1.09–1.40). 
Compared to LTD, surgical resection was associated with a 27% decreased risk of death 
(HR: 0.73; 95% CI: 0.67–0.80). 
 
Overall survival using other wait time cutoffs 
As shown in Table 13, wait time to surgery was dichotomized in a range of cutoff 
points from 50 to 100 days. In risk-adjusted overall survival, delayed patients consistently 
presented improved outcomes. Patients with a wait time longer than 50 days (HR: 0.93; 
95% CI: 0.87–0.99), 70 days (HR: 0.91; 95% CI: 0.85–0.97), 80 days (HR: 0.93; 95% CI: 
0.86–0.99), 90 days (HR: 0.91; 95% CI: 0.84–0.98), and 100 days (HR: 0.92; 95% CI: 
0.84–0.99) all demonstrated decreased risk of death compared to those without delayed 
surgery. 
 
Discussion 
To our knowledge, this is the first study utilizing large-scale data to investigate the 
association of surgical delay and HCC outcomes, as well as the factors associated with 
wait time to surgery. As the NCDB is a national database that consists of hospital registry 
data collected from commission-accredited cancer programs across the United States, 
findings generated from this study should be more generalizable than results obtained 
from studies of single centers. Although it is often assumed that delay in surgery has a 
harmful impact on cancer prognosis, we observed that delay was associated with more 
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optimal outcomes. This finding was consistently observed in unadjusted 5-year survival, 
as well as in covariates-adjusted overall survival based on wait time intervals ranging from 
50 to 100 days. With the exception of a study conducted by Akce et al. [19], which found 
delay to be associated with decreased risk of death among patients from the Department 
of Veterans Affairs treated with curative surgery, liver-directed therapy, or chemotherapy 
for BCLC stage C HCC (HR: 0.50; 95% CI: 0.37–0.67), other studies of hepatocellular 
carcinoma patients have reported that either prolonged wait time to surgery was linked 
with shortened survival [13-17] or that no significant association was observed [18]. In 
contrast to the majority of existing studies utilizing medical records, this retrospective 
analysis that is based on large comprehensive clinical data provides a different 
perspective. 
While findings of this study are counterintuitive, previous research that investigated 
the impact of delays in diagnosis-to-treatment, first hospital visit-to-treatment, and general 
practitioner referral-to-treatment in lung [143-145], colon [146], endometrial [147], and 
bladder [148] cancers also found similar trends in which prolonged wait time to surgery 
was associated with more optimal outcomes. A plausible explanation of this phenomenon 
is that tumor aggressiveness may influence delay, with more severe and advanced cases 
being referred to have more urgent treatments. This is also known as the waiting-time 
paradox, which is caused by the inclusion of patients with more severe conditions who 
invariably present early and have poor outcomes due to disease advancement [140]. In 
other words, the disease itself, such as its aggressiveness may have an influence on 
treatment delay; thus, delay could be a confounding factor [147]. A study that comprised 
769 patients surgically treated for colon cancer found that for every quartile increase in 
delay, odds of mortality decreased by a ratio of 0.78 [146]. The authors speculated that 
the advanced and high-risk cases were referred for workup and scheduled to be operated 
on sooner; therefore with prioritization, delay did not pose substantial risk of worsening 
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prognosis [146]. Furthermore, studies conducted in lung cancer patients suggested that 
cases with severe signs and higher symptom burden are likely to receive prompt treatment, 
while candidate patients of curative treatments might have to wait longer [143-145]. As a 
plausible explanation for our finding, the triage effect of operating on less urgent patients 
at a later time may have led to reasonable delays as a result of completing more 
comprehensive preoperative evaluation and staging for patients with less aggressive 
tumors. In our analysis, we observed that patients with primary tumor ≥2 cm and of poorly 
differentiated or undifferentiated grade (i.e. tumor biology) were significantly less likely to 
experience delay. Thus comparatively, patients with less aggressive tumor biology were 
treated at later times. These observations support our speculation about the practice of 
case prioritization. 
For comparison of 5-year survival between delayed versus non-delayed patients 
(Figure 6), the strength of association or difference in survival probability increased in 
advanced disease stage. For instance, among stage I patients who underwent resection, 
the difference in 5-year survival probability between the two wait time groups was only 
0.9% (53.5 subtract 52.6); however, stage III patients presented a survival difference of 
5.2% (27.2 subtract 22.0). A similar trend was also observed in patients treated with LTD, 
in which significant association was observed in stage III patients but not those with stage 
I disease. Likewise, Akce and colleagues demonstrated that delay was associated with 
decreased risk of mortality in HCC patients with BCLC stage C, but no association was 
detected for BCLC stage 0 and A or BCLC stage B [19]. These results further confirm our 
speculation about the practice of prioritizing more serious cases in advanced stage. 
Furthermore, our descriptive result indicated that 71.5% of delayed patients were treated 
in academic research cancer programs, while this number was lower for non-delayed 
patients (66.5%). In this cohort, patients who were treated in academic cancer centers 
had the most favorable outcome. Since academic hospitals are more suited to manage 
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the complicated and multi-disciplinary care that HCC surgeries often require [149], 
patients with less urgent conditions who were treated at a later time likely received more 
comprehensive preoperative assessment and postoperative follow-up offered in academic 
research cancer centers.  
Another explanation for our finding is that this study examined survival starting 
from diagnosis rather than from the onset of symptoms. It is known that an assessment 
that begins from an earlier time point would likely avoid lead-time-bias, and the increase 
in survival could be due to earlier diagnosis. In covariates-adjusted analysis, we were not 
able to account for certain potential confounding factors, including liver disease etiology, 
clinical indications of liver dysfunction (such as presence of hepatic encephalopathy and 
ascites), and laboratory values/scores (such as liver enzymes and Child-Turcotte-Pugh 
score) due to unavailability or largely missing values. Although risk-adjusted analyses 
included disease stage and tumor grade, stage is based on structural involvement and 
grade is determined by pathological appearance; these factors were not able to fully 
characterize direct liver function.  
 Currently, there is scarce research using covariates-adjusted analysis to 
investigate the predictors of delay in HCC surgery (Table 11). Consistent with our finding, 
a study using records abstracted from the Pennsylvania Cancer Registry found that HCC 
patients who underwent resection, lobectomy or partial hepatectomy were 52% less likely 
than patients treated with locoregional intervention to experience surgical delay [142]. In 
addition, the same study reported that male gender was a predictor of delay [142]. 
Corresponding to our results, a study that utilized the 1995-2005 NCDB file consisting of 
1,228,071 patients who underwent resection for gastrointestinal and breast cancers 
observed that African American race and Medicaid insurance were demographic factors 
significantly associated with prolonged wait time to treatment [150]. Similar to our finding, 
previous studies have shown that longer travel distance to facility was a predictor of 
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surgical delay in patients treated for cancers of the pancreas [151] and bladder [152]. We 
also found that cases with a primary tumor 2 cm or larger were less likely to experience 
delay. An explanation for this is that in comparison, resection resulted in a 30% decreased 
odds of delay, and 93.7% of resection procedures were performed on primary tumor ≥2 
versus 80.9% for LTD. Additionally, we observed that patients without delay were more 
likely to be treated in centers that did not perform liver transplantation; as 30.1% of non-
delayed patients were treated in non-transplant programs compared to 25.8% of delayed 
patients. This likely suggests that a number of patients underwent prompt surgery due to 
that transplant program was not available in where they received care.  
 There are several limitations in this study that should be noted. First, due to the 
retrospective nature of this database, information concerning to patient and physician 
treatment decision-making cannot be captured in detail. As a result, we could not assess 
the case prioritization approach in HCC surgical care, and its level of impact on our 
findings. As discussed previously, we were unable to examine certain clinical preoperative 
indications of liver dysfunction (presence of hepatic encephalopathy and hepatic ascites), 
and preoperative laboratory values/scores (liver enzymes and Child-Turcotte-Pugh score). 
Although data from which MELD score can be calculated are available (international 
normalized ratio of prothrombin time, bilirubin, and creatinine), this information is largely 
missing (67.3%) due to unavailability until 2010. Furthermore, since chemoembolization 
was coded as chemotherapy in the database, we were unable to distinguish between 
transarterial therapy and systemic chemotherapy; thus, we did not include chemotherapy 
in risk-adjusted analyses. In this cohort, survival analysis was based on all-cause death 
rather than HCC-specific death as cancer-specific survival data were not captured. These 
limitations should serve to call for an improvement in the quality of NCDB data and to 
include additional clinically relevant variables. Nevertheless, taking all factors into 
consideration, we believe that the strengths of this study outweigh its limitations.  
87 
 
 
 
To summarize, this analysis using NCDB data found that delay in HCC surgical 
treatment was associated with decreased risk of death, and this phenomenon was 
observed in patients who underwent LTD and resection. These findings should not be 
perceived as an encouragement to delay time to surgery or prolong wait time. Rather, the 
results suggest that a reasonable delay in surgery that is potentially based on tumor 
aggressiveness and severity does not appear to put patients at increased risk of death. 
Further studies are strongly warranted to understand and re-evaluate the advantages 
associated with undergoing early surgery for HCC. Additionally, it would be of significance 
to explore the impact of symptom-to-treatment delay or diagnostic delay on HCC 
outcomes.  
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Figure 3. Diagram for patient selection. Abbreviations: NCDB, National Cancer Database; 
LTD, local tumor destruction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary hepatocellular carcinoma         
(8180-8175) in NCDB 2004-2013   
(n=118,800) 
Final analytic cohort  
(n=12,102) 
 
Excluded: 
     Cases not treated with LTD or surgical resection (n=97,253) 
     Stage IV disease (n=545) 
     Unknown stage (n=2,601) 
     Sequence number other than “00” or “01” (n=2,776) 
     Underwent cancer directed surgery prior to definitive surgery                
     (n=342) 
Unknown wait time, or date of diagnosis was the same as date     
of definitive surgery (n=3,172)  
     Underwent definitive surgery past 2 years after diagnosis (n=9) 
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Figure 4. Patient distribution of wait time from diagnosis to surgery by month-intervals. 
Excluded definitive surgeries performed past two years after diagnosis date. 
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Table 10. Demographic and clinical characteristics based on wait time from diagnosis to 
surgery. 
 Wait Time to Surgery 
 
Characteristics 
≤60 days 
(n=7115)  n (%) 
>60 days 
(n=4987)  n 
(%) 
P 
Value 
 
Facility classification 
   
<.001 
     Comprehensive community cancer program 1487 (20.9) 916 (18.4)  
     Community cancer program 192 (2.7) 114 (2.3)  
     Academic research cancer program 4730 (66.5) 3563 (71.5)  
     Integrated network cancer program 468 (6.6) 318 (6.4)  
     Unknown/other 238 (3.4) 76 (1.5)  
Age at diagnosis 62.8 ± 11.8 62.0 ± 10.3 <.001 
Gender   <.001 
     Male 5055 (71.1) 3716 (74.5)  
     Female 2060 (29.0) 1271 (25.5)  
Race/ethnicity    <.001 
     Non-Hispanic Caucasian  4266 (60.0) 2793 (56.0)  
     Black 933 (13.1) 810 (16.2)  
     Asian 873 (12.3) 564 (11.3)  
     Hispanic 670 (9.4) 587 (11.8)  
     Unknown  373 (5.2) 233 (4.7)  
Insurance status  <.001 
     Private 2621 (36.8) 1726 (34.6)  
     Medicaid 873 (12.3) 829 (16.6)  
     Medicare 3159 (44.4) 2098 (42.1)  
     Not insured  266 (3.7) 197 (4.0)  
     Unknown  196 (2.8) 137 (2.8)  
Travel distance to facility   .015 
     ≤10 miles 2791 (39.2) 1971 (39.5)  
     10.1-50 miles 2626 (36.9) 1731 (34.7)  
     50.1-100 miles 819 (11.5) 593 (11.9)  
     >100 miles 754 (10.6) 613 (12.3)  
     Unknown 125 (1.8) 79 (1.6)  
Charlson-Deyo comorbidity score   .016 
     0 3486 (49.0) 2352 (47.2)  
     1 2070 (29.1) 1434 (28.8)  
     ≥2 1559 (21.9) 1201 (24.1)  
AJCC TNM stage    <.001 
     I 3980 (55.9) 2893 (58.0)  
     II 1811 (25.5) 1401 (28.1)  
     III 1324 (18.6) 693 (13.9)  
Alpha-fetoprotein level   <.001 
     Normal 1814 (25.5) 1313 (26.3)  
     Elevated 3446 (48.4) 2628 (52.7)  
     Unknown  1855 (26.1) 1046 (21.0)  
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Tumor size   <.001 
     <2 cm 780 (11.0) 724 (14.5)  
     2-5 cm 3485 (49.0) 2832 (56.8)  
     >5 cm 2584 (36.3) 1269 (25.5)  
     Unknown  266 (3.7) 162 (3.3)  
Tumor grade   <.001 
     Well differentiated  1241 (17.4) 902 (18.1)  
     Moderately differentiated  2198 (30.9) 1268 (25.4)  
     Poorly differentiated/undifferentiated  1063 (14.9) 461 (9.2)  
     Unknown  2613 (36.7) 2356 (47.2)  
MELD score  13.0 ± 8.6 13.1 ± 8.5 .75 
Surgical intervention of primary site   <.001 
     Local tumor destruction  3291 (46.3) 3057 (61.3)  
     Surgical resection  3824 (53.8) 1930 (38.7)  
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Table 11. Generalized linear mixed model to evaluate factors associated with wait time to 
surgery.  
 Wait Time to Surgery 
>60 days versus ≤60 days   
 
Characteristics 
Adjusted 
Odds Ratio 
 
95% CI 
P 
Value 
 
Facility classification  
 
 
  
     Comprehensive community cancer program Reference   
     Community cancer program 0.94 0.70–1.25 .65 
     Academic research cancer program 1.06 0.79–1.40 .71 
     Integrated network cancer program 0.89 0.62–1.29 .53 
Age at diagnosis 0.99 0.99–1.00 .017 
Gender    
     Male Reference   
     Female 0.85 0.78–0.94 <.001 
Race/ethnicity     
     Non-Hispanic Caucasian  Reference   
     Black 1.32 1.17–1.49 <.001 
     Asian 1.05 0.92–1.21 .46 
     Hispanic 1.12 0.97–1.29 .11 
Insurance status   
     Private Reference   
     Medicaid 1.28 1.13–1.45 <.001 
     Medicare 1.07 0.96–1.19 .21 
     Not insured  1.04 0.83–1.31 .71 
Travel distance to facility    
     ≤10 miles Reference   
     10.1-50 miles 1.00 0.91–1.10 .99 
     50.1-100 miles 1.03 0.89–1.19 .72 
     >100 miles 1.25 1.08–1.46 .004 
Charlson-Deyo comorbidity score     
     0 Reference   
     1 0.93 0.85–1.03 .17 
     ≥2 0.97 0.87–1.08 .56 
AJCC TNM stage     
     I Reference   
     II 1.07 0.97–1.18 .18 
     III 0.97 0.85–1.11 .67 
Tumor size    
     <2 cm Reference   
     2-5 cm 0.87 0.77–0.99 .032 
     >5 cm 0.70 0.60–0.81 <.001 
Tumor grade*    
     Well differentiated  Reference   
     Moderately differentiated  0.90 0.80–1.02 .11 
     Poorly differentiated/undifferentiated  0.70 0.60–0.83 <.001 
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     Unknown  1.00 0.88–1.13 .98 
Surgical intervention of primary site    
     Local tumor destruction  Reference   
     Surgical resection  0.70 0.63–0.78 <.001 
Alpha-fetoprotein level was not included due to insignificance in univariate analysis. 
*Missing values (41.1%) for tumor grade were grouped into “Unknown” category. 
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Figure 5. Kaplan-Meier survival estimates of wait time to surgery: A). Local tumor 
destruction (N=5254); B). Surgical resection (N=4996). 
A). 
 
B). 
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Figure 6. Survival probability of 1-year, 3-year, and 5-year, stratified by wait time, surgical 
intervention, and disease stage: A). Local tumor destruction; B). Surgical resection.  
A).  
  
B). 
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1-Year Survival 3-Year Survival 5-Year Survival
Non-delay 81.0 73.7 50.4 74.8 50.0 39.5 19.2 42.8 33.3 23.6 11.4 27.6
Delayed 86.4 82.2 64.4 82.7 50.9 41.9 23.7 45.1 32.6 28.7 11.9 29.1
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Non-delay 87.5 79.0 66.1 80.1 68.3 54.0 36.0 56.7 52.6 37.6 22.0 41.0
Delayed 89.2 83.1 78.4 85.4 71.3 57.5 43.1 61.8 53.5 39.2 27.2 44.1
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Table 12. Cox proportional hazards frailty model to estimate adjusted-risk of overall 
mortality.  
 
Characteristics 
 
Adjusted HR 
 
95% CI 
P 
Value 
 
Wait time to surgery 
   
 
     Wait time ≤60 days Reference   
     Wait time >60 days   0.93 0.87–0.99  .027 
Facility classification    
     Comprehensive community cancer program Reference   
     Community cancer program 1.04 0.83–1.30 .76 
     Academic research cancer program 0.86 0.79–0.94 <.001 
     Integrated network cancer program 1.05 0.91–1.21 .51 
Age at diagnosis 1.01 1.00–1.01 <.001 
Gender    
     Male Reference   
     Female 0.95 0.88–1.02 .14 
Race/ethnicity     
     Non-Hispanic Caucasian  Reference   
     Black 1.05 0.95–1.15 .38 
     Asian 0.76 0.68–0.84 <.001 
     Hispanic 1.01 0.90–1.12 .93 
Insurance status   
     Private Reference   
     Medicaid 1.12 1.00–1.24 .042 
     Medicare 1.12 1.03–1.22 .009 
     Not insured  1.04 0.85–1.26 .71 
Travel distance to facility    
     ≤10 miles Reference   
     10.1-50 miles 0.92 0.85–0.99 .029 
     50.1-100 miles 1.03 0.92–1.15 .60 
     >100 miles 1.03 0.92–1.16 .61 
Charlson-Deyo comorbidity score    
     0 Reference   
     1 0.99 0.92–1.07 .85 
     ≥2 1.19 1.09–1.29 <.001 
AJCC TNM stage     
     I Reference   
     II 1.11 1.03–1.20 .008 
     III 1.51 1.37–1.67 <.001 
Alpha-fetoprotein level    
     Normal Reference   
     Elevated 1.23 1.15–1.33 <.001 
Tumor size    
     <2 cm Reference   
     2-5 cm 1.03 0.93–1.14 .61 
     >5 cm 1.24 1.09–1.40 <.001 
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Tumor grade*    
     Well differentiated  Reference   
     Moderately differentiated  0.97 0.88–1.07 .53 
     Poorly differentiated/undifferentiated  1.08 0.95–1.23 .22 
     Unknown  1.07 0.97–1.18 .19 
Surgical intervention of primary site    
     Local tumor destruction  Reference   
     Surgical resection 0.73 0.67–0.80 <.001 
*Missing values (41.1%) for tumor grade were grouped into “Unknown” category. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. Adjusted-risk of overall mortality based on wait time cutoffs range from 50 to 
100 days, using 10-day increment. 
 
Wait Time to Surgery 
% Patients 
with Delay 
 
Adjusted HR 
 
95% CI 
  
P Value 
>50 days 49.8 0.93 0.87–0.99  .035 
>60 days 41.2 0.93 0.87–0.99   .027 
>70 days 33.7 0.91 0.85–0.97  .007 
>80 days 27.8 0.93 0.86–0.99  .048 
>90 days 23.3 0.91 0.84–0.98  .018 
>100 days 19.5 0.92 0.84–0.99  .040 
Each comparison was referenced to the non-delayed group. 
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
 
Summary of current research  
 According to the Global Burden of Disease 2015 study, there were 854,000 
incident cases and 810,000 deaths of liver cancer, which contributed to a total of 
20,578,000 disability-adjusted life-years [1]. Furthermore, primary liver cancer incidence 
increased by 75% between 1990 and 2015, and liver cancer is a major public health 
burden globally [1]. China, of all countries, has been most affected by liver cancer. In 
China, the biggest risk factor for developing HCC is chronic infection with viral hepatitis, 
particularly HBV. The disease burden of HBV is the highest among communicable 
diseases, and about 10 million Chinese living with chronic HBV are expected to die by 
2030, with a significant proportion due to HCC [153]. As the risk of developing HCC is 
significantly greater among patients with chronic hepatitis [36], HCC incidence could be 
reduced with the practice of recommended bi-annual cancer screening and antiviral 
therapy treatment. Among high-risk patients with chronic viral hepatitis, undergoing 
screening has shown to improve the rates for early HCC detection and eligibility for 
receiving curative treatments, and antiviral therapy plays a critical role in delaying liver 
disease progression and decreasing the likelihood of developing HCC.  
 Aim 1 of this dissertation investigated the practice, knowledge and self-perceived 
barriers to undertaking HCC surveillance among 352 patients with chronic HBV and/or 
HCV infection, and reported that only 50.0% of patients had routine bi-annual screening 
with ultrasound and AFP. Aim 2 examined the adherence rates and perceived barriers to 
NUC antiviral therapy among 369 patients chronically infected with HBV, and observed 
that over half (51.2%) of the subjects were measured with low adherence while a 
significantly smaller proportion had high adherence (16.5%). For both studies, a number 
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of socio-demographics and clinical factors were analyzed in multivariable regression 
analyses to evaluate the association of these factors with our outcomes of interest, and 
we found that rural residency was a significant predictor on patients’ HCC knowledge and 
antiviral medication adherence. Results from Aim 1 indicated that patients of rural regions 
had knowledge scores (based on questions about viral hepatitis transmission, and liver 
cancer prevention, progression and screening guidelines) that were 1.25 points lower than 
patients living in urban areas (P =0.002). In Aim 2, we found that patients residing in urban 
regions were 4.88 times more likely to have high medication adherence as opposed to low 
adherence compared to patients from rural regions. Over the past decade, China has 
experienced a major rise in economic development; however, there are serious issues in 
the health sector development with major gaps in urban and rural settings in areas of 
health services allocation, utilization and health outcomes [123]. HCC has been reported 
to have higher incidence and mortality rates in rural areas of China, which are likely 
contributed by the lack of medical resources and poor quality of medical services [154, 
155]. Moreover, there are lack of oncologists working in the rural regions, as hospitals 
located in rural regions are having a hard time retaining qualified oncologists [156].  
In addition to difficulty in accessing quality healthcare, chronic viral hepatitis has 
been considered as an economically disastrous disease in China, and costs are especially 
burdensome among individuals living in rural regions. It is estimated that less than 5% of 
rural patients are able to afford treatment for at least one year, as compared to 40% of 
those living in developed areas [123]. As a result, many rural patients infected with chronic 
hepatitis are unable to receive timely and quality treatment, and this is another reason 
rural HCC patients have a higher mortality. Our findings suggest that there is an urgency 
to implement more effective interventional measures to better educate patients residing in 
rural China, and to make healthcare more accessible and affordable. These 
recommended interventions include implementing more equitable access to clinical and 
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pharmaceutical services in rural and remote areas, increasing reimbursement for 
pharmaceutical treatments to reduce the barriers in medication affordability, urging the 
government to enter into negotiations with the generic drug manufacturers of entecavir to 
provide less costly drugs, urging the government to accelerate its public investment into 
public health system, and organizing mass public awareness campaigns to increase 
knowledge about management of chronic hepatitis and HCC preventive strategies [123]. 
Using structured questionnaires to evaluate patients’ self-identified barriers, we 
found that the most commonly reported barriers were closely associated with an 
inadequate knowledge and poor health awareness. For instance, 41.5% of participants 
from Aim 1 reported that they did not know screening for HCC existed, 38.3% stated that 
there is no need for screening because of no symptom or physical discomfort, and 45.1% 
of patients from Aim 2 cited forgetfulness as the reason for skipping NUC medications. 
These results further show that health education in liver cancer prevention is critical to 
enhance compliance to HCC surveillance and antiviral treatment. There is also the need 
to provide accessible and accurate information to the high-risk patients. Healthcare 
providers should work closely with community health leaders to better inform high-risk 
patients about diseases associated with chronic viral hepatitis, as well as clinical 
management access, prevention and control measures, and recommended lifestyles [123]. 
Patients should fully understand that HBV and HCV are major risk factors for developing 
HCC and other serious adverse conditions of the liver, and that these health conditions 
require regular monitoring and the appropriate treatment for viral suppression.   
Although antiviral medications are available to slow down disease progression in 
patients with chronic viral hepatitis, a number of these patients will eventually develop 
HCC. Due to the poor prognosis of HCC, curative treatments such as RFA, surgical 
resection and transplantation are usually only offered in the early-stage, indicating that 
early active treatment is critical to increase the chance of survival. However, based on 
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findings from Aim 3, we found that surgical delay in LTD and hepatic resection was 
associated with a more favorable 5-year survival and risk-adjusted long-term overall 
survival. Using a range of cutoff values to define surgical delay, including 50, 60, 70, 80, 
90 and 100 days, all cutoffs demonstrated that prolonged wait time from diagnosis to 
surgery was significantly correlated with a decreased risk of death. 
These findings we obtained do not align with our initial hypothesis that a longer 
wait time to surgery would adversely affect prognostic outcomes. This hypothesis was 
developed based on previously published literature conducted in HCC patients who 
underwent loco-regional therapies, hepatic resection, and other HCC-directed treatments 
[13-19]. Previous studies found that delay from diagnosis to surgery was associated with 
shortened survival and an increased risk of mortality [13-19]. We also developed this 
hypothesis because it is known that early HCC detection would improve the patients’ 
chance to receiving curative surgeries [138]. Unfortunately, it is difficult to make direct 
comparison of our findings with those of previously published literature due to major 
differences in the data sources used. We utilized a large national comprehensive oncology 
database as opposed to medical records from single treatment centers, and while previous 
studies included a number of clinically relevant values in their analyses (i.e. disease 
etiology, liver dysfunction indicators, liver enzymes), our risk-adjusted models were 
generated with the absence of such variables due to unavailability. This limitation was 
recognized, but could not be overcome.  
It is important to note that a number of similar studies conducted in lung [143-145], 
colon [146], endometrial [147], and bladder [148] cancers have also produced 
counterintuitive results, and suggested these findings are likely attributed to the waiting-
time paradox, in which patients with more severe and advanced conditions are being 
referred for prompt treatment. These patients who are being operated on early are more 
likely to have poor outcomes due to disease advancement, while patients with less 
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aggressive tumors are being treated later and receive more comprehensive preoperative 
evaluation and clearance. As a result of the prioritization approach, surgical delay did not 
appear to have a harmful impact on survival because this triage selection process 
produced two treatment groups of patients (non-delay vs. delayed) with different clinical 
conditions. This phenomenon is also evident by our findings in which patients with primary 
tumor larger than 2 cm, poorly differentiated or undifferentiated grade, and advanced 
disease stage were less likely to experience surgical delay. Given the results obtained, 
HCC surgical care prioritization seems to be a reasonable approach, as a prolonged wait 
time to surgery that is likely based on tumor aggressiveness and advancement did not 
increase patients’ risk of death.  
 
Limitations 
This dissertation consists of both primary survey data collected among Chinese 
hospital patients and a national hospital-based oncology registry data. There are several 
limitations associated with the collection and use of primary data in aims 1 and 2. A major 
limitation is that electronic medical record (EMR) systems are not currently well-
established in the vast majority of medical institutions in China. As our studies were 
conducted in two tertiary hospitals in Shanghai and Wuhan, the collected survey data were 
based on patients’ self-report and formal verification for data accuracy could not be 
performed. To improve the quality of epidemiologic and clinical research in China, it is of 
importance for China to establish and widely implement the EMR system. This universal 
system of EMR should be the same across the entire country, and should be accessible 
to any medical institution and health clinic, while still providing privacy and security of 
patient information.  
Furthermore, these studies were conducted among Chinese hospital patients in 
major tertiary hospital of large urban cities, Shanghai and Wuhan, with population sizes 
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comparable to New York City and Chicago, respectively. We were not able to fully capture 
the knowledge level, attitudes and self-identified barriers for cancer screening and 
medication treatment among patients from rural regions. Since major gaps in healthcare 
disparities, economic development, and cultural customs exist between urban and rural 
regions in China, findings generated from these studies are subject to geographical 
limitations. Another limitation is that because we used convenience sampling method, 
there is the possibility that sampling bias was introduced and this may limit the external 
validity of the studies’ results. In comparison to population-based probability sampling, 
convenience sampling produces estimates that are more generalizable to the sample 
studied, whereas results produced from population based sampling could yield more 
representative estimates of the target population. Additionally, our patient recruitment 
design is subject to potential selection bias. The reason is that patients who visit 
healthcare facilities tend to have better health awareness and are therefore more likely to 
stick with disease management plans. 
For Aim 3, the biggest limitation is that the NCDB does not have information on a 
number of preoperative clinically relevant factors, including liver dysfunction (i.e. hepatic 
encephalopathy, ascites) and laboratory values (i.e. MELD score, liver enzymes, Child-
Turcotte-Pugh score). As a result, we were not able to adjust for these potential 
confounding factors, which could have had an impact on our findings. Often times, cancer 
registry databases do not provide information on cancer recurrence, and the NCDB is no 
exception. We were not able to evaluate recurrence-free survival or the impact of surgical 
delay on HCC recurrence. Furthermore, because chemoembolization was coded as 
chemotherapy, we were unable to determine whether a number of patients underwent 
trans-arterial therapy or systemic chemotherapy treatment. Lastly, without available 
information on patient and physician treatment decision-making, we can only speculate 
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that the counterintuitive findings were attributed to surgical prioritization based on tumor 
severity and advancement, but no definitive conclusion can be made.  
 
Future directions 
Future research that aims to evaluate HCC screening practice or antiviral 
medication adherence in high-risk patients should consider to recruit participants from 
community-based settings. In the past, there was no well-established primary care system 
in China, but in recent years, China has put substantial emphasis into primary care [157, 
158]. This enables routine blood screening of the general population, making early 
diagnosis of HBV and HCV possible. One method for identifying infected individuals in 
local communities and acquire their contact information is to work with primary care 
physicians, who should have a list of individuals tested positive for HBV or HCV infection 
through annual blood exams. Given the approval for data usage and necessary patient 
consent, researchers would be able to recruit study subjects in community settings 
through telephone interviews and potentially door-to-door visits (note that Chinese 
populations do not respond well to mailed brochures). This recruitment process would 
likely yield a more representative sampling, as it would allow investigators to collect 
information from many high-risk patients who do not visit hospitals or are not receiving the 
appropriate specialty care (which can be due to low health awareness, indifference about 
disease condition, and avoiding medical care costs). Additionally, similar studies can be 
conducted in endemic regions, as a number of regions in China are considered as high 
endemic areas for developing HCC. For instance, the city of Qidong, which is located in 
the north shore of the Yangtze River, is known to have the highest population-based 
incidence of liver cancer across China and in the world [159].  
Furthermore, future studies should focus on Chinese patients residing in rural and 
impoverished regions. Based on our findings, urban patients were more likely to have high 
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medication adherence and were more compliant with undergoing HCC screening 
compared to residents of rural regions. Since rural patients represented just 19.2% and 
14.2% of our samples for aims 1 and 2, respectively, we were not able to evaluate the 
research objectives solely using rural patients due to insufficient samples. In China, 
disparities in social and economic development, as well as healthcare quality exist in the 
urban and rural regions. These include but are not limited to income and education level, 
healthcare accessibility and utilization, qualifications of local healthcare providers, medical 
resources at treatment facilities, and health insurance coverage. Thus far, no published 
studies has focused to evaluate the practice, knowledge level, and perceived barriers for 
liver cancer prevention and control among high-risk rural Chinese patients. As major 
health disparities exist in different regions of China and rural patients are known to have 
higher incidence and mortality rates for HCC [154, 155], it is of significance to assess the 
practice of HCC prevention and surveillance in non-urban settings.  
In terms of clinical implication, one potential strategy to improve HCC surveillance 
in China is through the development and utilization of at-home screening kits, and there 
is a need to conduct extensive research in this area. As known, the most important 
mechanism for improving curative rates of HCC is to enhance early detection rates, as 
patient survival largely depends on the disease stage [29]. However, current medical 
technologies used in surveillance can be expensive for certain populations in China [160]. 
Due to financial restraints and depending on where patients receive care, not all high-risk 
Chinese patients can have HCC screening covered through medical insurance [160]. The 
other issue in undergoing routine surveillance is that there is limited number of healthcare 
practitioners in China [154, 155]. This is especially the case in rural and impoverished 
areas, where medical resources are scarce and there is lack of well-trained healthcare 
providers [160]. One company has developed an at-home screening kit for detecting 
colorectal cancer and advanced precancerous lesions through detecting tumor specific 
106 
 
 
 
KRAS mutations, abnormal NDRG4, bone morphogenetic protein 3 methylation, and 
hemoglobin immunoassays stool samples [161]. For at-home cervical cancer screening, 
measures based on self-collected vaginal samples for HPV testing are available [162, 163]. 
Moreover, recently, highly sensitive nanoarray sensors for exhaled volatile organic 
compounds have been created for the detection of lung cancer using breath samples [164, 
165]. As of this date, at-home screening kit for HCC has not been developed, and there is 
still a long way to go. Nevertheless, at-home screening tools would likely address the 
aforementioned gaps in China, and would be worth the effort to conduct research in this 
field to develop a kit with a satisfying sensitivity and specificity [160].   
A meta-analysis consisting of 16 randomized clinical trials, published on JAMA 
Internal Medicine, found that text message-based intervention roughly doubled the odds 
of medical adherence in patients treated for various chronic diseases [161]. This increase 
translated to an absolute increase of 17.8% (from 50% to 67.8%) [161]. Similarly, in Aim 
2, we observed that patients who received regular reminders from family members were 
3.13 times more likely to have high medication adherence. Since messaging can serve as 
a useful tool for behavior change in disease prevention and monitoring, healthcare 
providers should work with policy makers to consider in widely implementing and adopting 
the use of automated computer programs in hospitals and clinics. This would allow daily 
reminder messages to be sent to patients who are enrolled in the disease management 
programs, and who are prescribed with life-term medications for treating chronic illnesses 
(this would include patients treated for chronic hepatitis). An advantage of text messaging 
over other interventions (such as patient education, counseling, allied health support) is 
the ease of administration, in which a computerized program is built to generate messages 
in an automated fashion [166].   
Despite the availability of HBV antiviral therapy in China, the proportion of patients 
who actually receive treatment is low, and the main barrier to treatment is the cost [132]. 
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Our findings should assist health policy makers to have a better understanding on the 
magnitude of the economic burden of HBV-related illnesses in China. In addition, there is 
the need for policy makers to design and implement strategic plans to allocate more 
medical resources in rural and under-developed regions in China to improve chronic 
hepatitis management, as well as developing plans that would allow rural patients who 
seek care in urban hospitals to receive health insurance coverage. In China, compared to 
urban residents, patients of rural regions are unable to receive the same healthcare 
coverage and reimbursements when treated or cared in urban hospitals [167, 168]. This 
is largely attributed by the household registration policy [167], in which residents are 
classified as rural or urban based on their residential location [90]. Based on this 
registration, rural residents are provided with the government-led insurance program 
known as New Rural Cooperative Medical System [114], which usually has inferior 
coverage and inconvenient reimbursement procedures compared to insurance programs 
offered to urban residents [167]. The household registration policy was established to 
control population migration and to determine eligibility for state-provided benefits [90]. 
For the next step, it would be of critical importance for policy makers to develop plans to 
address this issue, so that rural patients residing in less resourceful areas could visit urban 
hospitals to obtain higher quality of care and have it covered. 
From using the NCDB database, we obtained counterintuitive findings and that our 
results do not align with the majority of published literature. Thus, additional research is 
strongly warranted to re-evaluate the relationship of prolonged surgical wait time and HCC 
outcomes. Similar research should consider using the Surveillance, Epidemiology, and 
End Results (SEER)-Medicare-Linked database. Different from the NCDB, which is 
sourced from hospital registry data, the SEER-Medicare data reflect the linkage of two 
large population-based data sources on cancer patients. SEER collects data on cancer 
patient demographics, tumor site and morphology, stage at diagnosis, first course 
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treatment, and survival follow-up from population-based cancer registries that cover 28% 
of the U.S. population. A number of studies have utilized SEER-Medicare to investigate 
the impact of treatment delay or surgical wait time on patient outcomes in melanoma, 
breast and colon malignancies [169-171]. Although the NCDB has a strength in capturing 
more cancer cases and contains treatment hospital characteristics, the major advantage 
of SEER lies in its population-based sampling approach; whereas the NCDB collects data 
from convenience sampling of hospitals accredited by the Commission on Cancer (CoC). 
As a result, patient demographics within SEER data are more comparable to that of the 
general U.S. population [172].  
In order to better understand how the prioritization approach has an impact on 
post-operative HCC survival, and to evaluate the level of impact prioritization has on 
survival, future studies conducted prospectively in clinical settings are warranted. Given 
that we used secondary data, we were unable to examine the patient and physician 
treatment decision-making process, and were not able to determine why certain patients 
had shorter or longer wait times. Although we found an association between surgical delay 
and long-term HCC survival, no temporal relationship can be determined. The proposed 
prospective studies should focus on assessing the decision-making process and identify 
the factors or reasons that influence undergoing prompt or delayed HCC surgery. 
Structured questionnaires can be provided to patients who are eligible for HCC-directed 
surgeries and their treating physicians to assess treatment preferences, reasons for 
treatment of choice, and concerns or barriers to receiving surgery. Additionally, 
researchers should examine whether patients who undergo surgery at a later time have 
comparatively better liver function, tumor biology, and less disease severity or 
advancement. Lastly, patients should be followed prospectively for five years post-surgery 
to compute for HCC-specific survival.  
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As of this date, no study has explored the impact of symptom-to-treatment delay 
or diagnostic delay on the prognosis of HCC. To evaluate the impact of treatment delay 
from the onset of symptoms would likely serve to avoid lead time-bias. This would 
eliminate the systematic error of an increased survival due to detecting disease at an 
earlier stage. Moreover, examining symptom-to-treatment delay would also allow 
researchers to better evaluate patient-level delay. Patient delay can be defined as time 
from the patients’ first self-discovery of symptoms to time of clinic visit for medical 
evaluation by a physician; whereas provider delay or health system delay is related to 
delay in diagnosis and delay in the initiation of cancer treatment [173, 174]. 
 
Conclusions  
 Overall, this dissertation fills the gaps in knowledge about the adherence, attitudes, 
and self-reported barriers to undertaking preventive HCC screening and NUC antiviral 
therapy among the high-risk patients, as well as the association between surgical delay 
and long-term prognosis among patients who have developed HCC. These findings could 
assist healthcare providers and researchers to develop more effective educational 
programs in China to improve patients’ awareness, knowledge level, attitudes, and 
perceptions about HCC prevention and control; with an emphasis on viral hepatitis 
management and undergoing timely HCC surveillance. These interventional programs 
should also target patients residing in rural areas and with low socioeconomic status. 
Moreover, there is a need for policy makers to step in, and to work collaboratively with 
healthcare professionals to develop strategic plans that would make pharmaceutical care 
more affordable in treating chronic hepatitis. Furthermore, our findings strongly call for the 
adaptation of a universal EMR system across China to enhance epidemiologic and clinical 
research. For treating patients with HCC, contrary to what is assumed, using a national 
hospital-based cancer registry, our study added new evidence that delay in HCC surgery 
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was associated with a decreased risk of mortality. This study calls for the use of other 
large registry database to further explore the relationship of prolonged surgical wait time 
and HCC prognosis, and indicates the need to conduct prospective studies to better 
understand and validate the prioritization approach in HCC surgical care.  
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APPENDIX A 
Comparison of hepatocellular carcinoma surveillance guidelines published from 
different professional organizations.   
 
Organization Date 
published 
Method Interval Target population 
American Association for the Study 
of Liver Diseases (AASLD) [36] 
 
Link: 
https://aasldpubs.onlinelibrary.wiley. 
com/doi/abs/10.1002/hep.29913 
2018 Ultrasound, 
with or without 
AFP 
Every 6 
months 
Cirrhotic patients, noncirrhotic 
HBV carriers with a family 
history of HCC, noncirrhotic 
Africans and African 
Americans with HBV, 
noncirrhotic Asian male HBV 
carriers past the age of 40 
years, noncirrhotic Asian 
female HBV carriers past the 
age of 50 years. 
European Association for the Study 
of Liver (EASL) [175] 
 
Link:  
https://www.journal-of-
hepatology.eu/article/S0168-
8278(18)30215-0/fulltext  
2018 Ultrasound  Every 6 
months 
Cirrhotic patients, noncirrhotic 
HBV carriers with a family 
history of HCC, noncirrhotic 
HBV carriers with active 
hepatitis, noncirrhotic patients 
with chronic HCV and 
advanced liver fibrosis (F3). 
Asian Pacific Association for the 
Study of Liver (APASL) [30] 
 
Link:  
http://www.clubepatologiospedalieri.it
/wp-content/uploads/2018/02/M-
Omata-APASL-Guidelines-HCC-
2017-Hep-Int.pdf 
2017 Combination 
of AFP and 
ultrasound 
Every 6 
months 
Cirrhotic patients with HBV or 
HCV infection, chronic HBV 
carriers 
National Comprehensive Cancer 
Network (NCCN) [176] 
 
Link:  
http://www.lidebiotech.com/nccn/20.p
df 
2017 Ultrasound  Every 6 
months 
Cirrhotic patients, noncirrhotic 
HBV carriers 
National Health and Family Planning 
Commission of the People’s 
Republic of China [177] 
 
Link:  
https://www.karger.com/Article/FullT
ext/488035 
2018 Combination 
of AFP and 
ultrasound 
Every 6 
months 
Cirrhotic patients, noncirrhotic 
HBV or HCV carriers, patients 
with a family history of HCC 
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APPENDIX B 
QUESTIONNAIRE: PRACTICE, KNOWLEDGE AND BARRIERS FOR SCREENING OF 
HEPATOCELLULAR CARCINOMA AMONG HIGH-RISK CHINESE PATIENTS 
 
 
Part I. 
Please provide some basic information about yourself 
1. Age：         _______ 
2. Gender：     A. Male B. Female 
3. Current region of residence：  A. Rural  B. Urban 
4. Household registration:   A. Rural  B. Urban 
5. Education level：  
A. Middle school or below  B. High school  
C. College or above 
6. Annual household income：  
A. <40,000 RMB    B. 40,000 - 80,000 RMB   
C. 80,000 - 150,000 RMB   D. >150,000 RMB 
7. Medical insurance： 
A. Urban Employee’s Basic Medical Insurance        
B. Urban Resident Basic Medical Insurance            
C. New Rural Cooperative Medical System  
D. Other: ________________               
E. Out-of-pocket 
8. Any immediate family member diagnosed with liver cancer? Yes  or  No 
9. How long have you been diagnosed with hepatitis infection: ________ 
10. Do you have liver cirrhosis?     Yes  or  No 
11. Do you have any of the following chronic condition(s)? 
      A. Hypertension  B. Diabetes  C. Cardiovascular disease  
      D. Stroke   E. Cancer     
      F. Other chronic condition：_____________  G. None 
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Part II. 
1. Have you ever received ultrasound of the liver?   Yes  or  No     
2. Have you ever had alpha-fetoprotein (AFP) of the liver? Yes  or  No     
3. Prior to participate in this study, did you know about the purpose of AFP test? 
        Yes  or  No     
 
If answered YES to have received ultrasound or AFP 
 Please state when was the last time you had ultrasound: ___________ 
 Please state about how often do you get ultrasound: ___________ 
 Please state when was the last time you had AFP: ___________ 
 Please state about how often do you get AFP: ___________ 
 Were the screening tests provided by your employer or did you choose to 
undergo screening? ____________ 
 If provided by employer, please state the type of employment 
organization: ___________ 
 
 
If answered NO, please choose the reason(s) for not having undergone screening 
(more than one choice is allowed): 
 Do not know the benefits of screening  (      ) 
 Financially difficult to afford screening  (      ) 
 Not aware that screening for liver cancer exists  (      ) 
 Since liver cancer is difficult to treat, why bother undergo screening  (      ) 
 No symptoms or discomfort  (      ) 
 Lack of recommendation from physicians  (      ) 
 Lack of time  (      ) 
 Difficulty in accessing medical facilities  (      ) 
 Other (please state the reason): _____________ 
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Part III. For the questions below, please choose the correct answer 
1. Is HBV or HCV commonly transmitted through consuming contaminated food? 
Yes or No 
2. Can HBV or HCV be transmitted through sexual intercourse?   
Yes or No 
3. Is excessive alcohol consumption considered a risk factor for liver cancer? 
Yes or No 
4. Have you heard of aflatoxin and its role in liver cancer?    
Yes or No 
5. Does chronic hepatitis have to cause cirrhosis before developing liver cancer? 
Yes or No 
6. Can liver cancer metastasize to other organs in the body?    
Yes or No  
7. Do symptoms usually show up in the early stage of liver cancer?   
Yes or No 
8. Which of the choices are common symptoms of liver cancer?   
A. Yellow of the skin    B. Persistent headaches 
C. Shortness of breath   D. Unexplained weight loss    
9. Which of the following lifestyles are important to prevent from developing liver 
cancer? 
A. Smoking cessation   B. Alcohol drinking cessation   
C. Limit the intake of salty food D. Consumption of high fruit and vegetables 
E. All the above 
10. Which of the two choices are the most common tests used for liver cancer 
screening? 
A. X-ray     B. AFP 
B. Ultrasound    D. CT scan 
11. How often should patients with chronic hepatitis undergo liver cancer screening?  
A. Whenever symptoms appear   B. At least every half year   
C. Once every two years   D. Don’t know 
12. When should patients with chronic hepatitis to start undergo liver cancer 
screening? 
A. Whenever symptoms appear  B. Men at age 35, women at age 45  
C. Men at age 45, women at age 55  D. Don’t know 
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APPENDIX C 
QUESTIONNAIRE: ADHERENCE AND PERCEIVED BARRIERS TO ORAL ANTIVIRAL 
THERAPY FOR CHRONIC HEPATITIS B 
 
 
Part I.  Basic Demographic and Clinical Information 
1. Age: ______ 
2. Gender:           A. Male    B. Female 
3. Current region of residence:       A. Rural     B. Urban 
4. Education level: 
A. Middle school or below  B. High school    C. College or above 
5. Annual household income (RMB): 
A. <50,000           B. 50,000 to 80,000           
C. 80,000 to 150,000           D. >150,000 
6. Health insurance status: 
A. Urban Employee’s Basic Medical Insurance        
B. Urban Resident Basic Medical Insurance            
C. New Rural Cooperative Medical System  
D. Other: ________________               
E. Out-of-pocket 
7. How long have you been diagnosed with HBV infection?  ________ 
8. Do you have liver cirrhosis?  Yes  or  No 
 
 
 
 
Part II.  The 8-item Morisky Medication Adherence Scale (MMAS-8). 
 
 Patient 
answer 
(Yes or No) 
1. Do you sometimes forget to take your antiviral medication(s)?  
2. People sometimes miss taking their medication(s) for reasons 
other than forgetting. Thinking over the past two weeks, were 
there any days when you did not take your antiviral medication(s)? 
 
136 
 
 
 
3. Have you ever cut back or stopped taking your antiviral 
medication(s) without telling your doctor because you felt worse 
when you took it? 
 
4. When you travel or leave home, do you sometimes forget to 
bring along your antiviral medication(s)? 
 
5. Did you take all your antiviral medication(s) yesterday?  
6. When you feel like your symptoms are under control, do you 
sometimes stop taking your antiviral medication(s)? 
 
7. Taking antiviral medication(s) every day is a real inconvenience 
for some people. Do you ever feel hassled about sticking to your 
treatment plan? 
 
8. How often do you have difficulty remembering to take all your 
antiviral medication(s)? 
A. Never/Rarely 
B. Once in a while 
C. Sometimes 
D. Usually 
E. All the time 
 
Use of the ©MMAS is protected by US and International copyright laws. © 2006 
Donald E. Morisky  Permission for use is required. A license agreement is available 
from: Donald E. Morisky, MMAS Research (MORISKY), 294 Lindura Court, Las Vegas, 
NV 89135-1415; dmorisky@gmail.com. 
 
 
 
 
 
Part III. Potential Barriers to Antiviral Medication Adherence 
If you did not obtain a score of 8 on MMAS scale, please check the reason (s) that apply: 
 
 Forgetfulness  (      ) 
 Cannot tell the difference between taking and not taking medication(s)  (      ) 
 Feel better already and do not think it is necessary to continue  (      ) 
 Have experienced side effects or worry about potential side effects  (      ) 
 Physician did not inform me about importance of taking medication(s) regularly 
(      ) 
137 
 
 
 
 Ran out of pills and have no time to refill  (      ) 
 Multiple medications are taken daily and cannot remember the dose  (      ) 
 All medication(s) are paid out-of-pocket; it is difficult to afford them  (      ) 
 Insurance does not provide coverage when cost exceeds the limit (      ) 
 Do not want others to know that I am taking medication(s)   (      ) 
 Other reason (please specify): ___________ 
 
 
 
 
Part IV. Treatment-related Characteristics and Perception of Disease 
1. Which HBV antiviral medication(s) are you taking? _________ 
2. How long have you been taking the antiviral medication(s)?   _________ 
3. Other than antiviral medication(s), are you also taking other medication (e.g. 
traditional Chinese Medicine) or utilizing other treatments for HBV?  
A. If yes, please specify: _________     B. No 
4. Do you have other chronic diseases? If so, how many?  _________  To treat 
these illnesses, how many pills are you taking per day? (does not include HBV 
medication(s)) __________ 
5. Do you understand everything the physician says during your consultation about 
HBV medication(s)? 
A. Yes                  B. No 
6. Are you using any memory aids (e.g. phone alarm, clock alarm) for antiviral 
treatment?  
A. Yes                  B. No 
7. Do your family members remind you to take antiviral treatment on time? 
A. Yes                  B. No 
8. Do you think that antiviral treatment is effective? 
A. Yes                  B. No                    C. I don’t know 
9. How would you rate your current HBV condition?  
A. Severe             B. Moderate         C. Mild           D. Don’t know 
10. How would you rate your overall health condition? 
A. Very good        B. Good                C. Fair           D. Poor 
